Healthcare Corp of America (SWCAU) 10-KT 13 Mar 14 2013 FY Annual report (with FYE transition) Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	6 Months Ended
	Jun. 30, 2013	Mar. 10, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'Healthcare Corp of America	'
Entity Central Index Key	'0001514682	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'SWCA	'
Entity Common Stock, Shares Outstanding	'	8,832,692
Document Type	'10-KT	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-13	'
Document Fiscal Period Focus	'FY	'
Document Fiscal Year Focus	'2013	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filers	'Yes	'
Entity Current Reporting Status	'No	'
Entity Public Float	$20,400,000	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2013	Dec. 31, 2012
Assets	'	'
Cash and cash equivalents	$1,792,026	$1,791,134
Prepaid expenses and other current assets	322,638	619,271
Total current assets	5,383,847	5,404,729
Inventory	442,945	544,004
Accounts receivable	1,251,579	1,126,846
Rebates receivable	1,574,659	1,323,474
Property and equipment, net	1,236,734	1,114,055
Investment held in trust	8,652,482	0
Deferred financing costs, net	548,394	0
Software, net	262,142	0
Other assets	443,251	83,686
Total assets	16,526,850	6,602,470
Liabilities, Redeemable Securities and Stockholders’ Deficit	'	'
Total liabilities	16,156,733	10,553,639
Stockholders’ deficit:	'	'
Preferred stock, $.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding at June 30, 2013 and Preferred stock, no par value; 592,500 shares authorized; 592,500 shares issued and outstanding; liquidation preference of $1,481,250 at December 31, 2012	0	2,362,517
Common stock, $.0001 par value; 30,000,000 shares authorized; 8,953,494 shares issued and outstanding at June 30, 2013 and Common stock, no par value; 50,000,000 authorized; 40,000,009 shares issued and outstanding at December 31, 2012	895	4,175,856
Additional paid-in capital	16,423,417	150,000
Accumulated deficit	-24,705,834	-10,639,542
Total stockholders’ deficit	-8,281,522	-3,951,169
Total liabilities, redeemable securities and stockholders’ deficit	16,526,850	6,602,470
Current liabilities:	'	'
Accounts payable	5,214,355	4,431,366
Total current liabilities	9,024,393	9,968,774
Accrued expenses	2,428,033	568,528
Deferred revenue	495,286	638,223
Bridge notes	0	4,192,954
Line of credit	534,343	0
Current portion of capital leases	189,989	137,703
Other current liabilities	162,387	0
Incentive Notes	2,771,514	0
Capital leases, net of current portion	658,092	399,382
Derivative liabilities	3,559,188	121,350
Other liabilities	143,546	64,133
Commitments and contingencies	'	'
Redeemable securities:	'	'
Redeemable common stock, $.001 par value; 839,965 shares issued and outstanding	8,651,639	0
Total redeemable securities	$8,651,639	$0

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Jun. 30, 2013	Dec. 31, 2012
Preferred stock, par value (in dollars per share)	$0.00	$0
Preferred stock, shares authorized	1,000,000	592,500
Preferred stock, shares issued	0	592,500
Preferred stock, shares outstanding	0	592,500
Preferred Stock, Liquidation Preference, Value	'	$1,481,250
Common stock, par value (in dollars per share)	$0.00	$0
Common stock, shares authorized	30,000,000	50,000,000
Common stock, shares issued	8,953,494	40,000,009
Common stock, shares outstanding	8,953,494	40,000,009
Redeemable Common Stock [Member]	'	'
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares issued	839,965	839,965
Common stock, shares outstanding	839,965	839,965

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Sales	$24,328,860	$27,305,795
Cost of sales	23,309,725	26,148,118
Gross profit	1,019,135	1,157,677
Operating expenses:	'	'
Selling, general and administrative	10,815,273	7,603,458
Loss from operations	-9,796,138	-6,445,781
Other income (expense):	'	'
Interest expense	-4,332,317	-1,130,184
Change in fair value of derivative liabilities	62,163	0
Total other income (expense)	-4,270,154	-1,130,184
Loss before provision for income taxes	-14,066,292	-7,575,965
Provision for income taxes	0	0
Net loss	-14,066,292	-7,575,965
Less: Deemed dividend to preferred stockholders	-3,532,858	0
Net loss attributable to common stockholders	($17,599,150)	($7,575,965)
Earnings per share:	'	'
Basic and diluted loss per share (in dollars per share)	($2.57)	($0.19)
Weighted average number of shares outstanding (in shares)	6,851,819	38,939,909

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT AND REDEEMABLE SECURITIES (USD $)	Total	Redeemable Common Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]
			Stockholders' Deficit [Member]	Stockholders' Deficit [Member]	Stockholders' Deficit [Member]	Stockholders' Deficit [Member]
Beginning balance at Dec. 31, 2011	$2,824,234	$0	$2,362,517	$3,525,294	$0	($3,063,577)	$0
Beginning balance (in shares) at Dec. 31, 2011	'	0	0	37,879,809	'	'	0
Issue stock to stockholders	650,562	0	0	650,562	0	0	0
Issue stock to stockholders (in shares)	'	0	0	2,120,200	'	'	0
Issuance of warrants	250,000	0	0	'	250,000	0	0
Redemption of common stock	-100,000	0	0	0	-100,000	0	0
Payments to Series A Holders	0	'	'	'	'	'	'
Net loss	-7,575,965	0	0	0	0	-7,575,965	0
Ending balance at Dec. 31, 2012	-3,951,169	0	2,362,517	4,175,856	150,000	-10,639,542	0
Ending balance (in shares) at Dec. 31, 2012	'	0	0	40,000,009	'	'	0
Receipt of stock previously redeemed	0	0	0	0	100,000	0	-100,000
Receipt of stock previously redeemed (in shares)	'	0	0	0	'	'	-500,000
Stock based compensation	480,000	0	0	0	380,000	0	100,000
Stock based compensation (in shares)	'	0	0	0	'	'	500,000
Effect of recapitalization - reverse merger with Selway Capital Acquisition Corp	-2,362,517	0	-2,362,517	-4,175,856	4,175,856	0	0
Effect of recapitalization - reverse merger with Selway Capital Acquisition Corp (in shares)	'	0	0	-40,000,009	'	'	0
Issue stock to stockholders	0	0	0	520	-520	0	0
Issue stock to stockholders (in shares)	'	0	0	5,200,000	'	'	0
Selway equity at closing	20,600,000	0	0	250	20,599,750	0	0
Selway equity at closing (in shares)	'	0	0	2,500,000	'	'	0
Common stock issued upon conversion of bridge notes	3,159,624	0	0	32	3,159,592	0	0
Common stock issued upon conversion of bridge notes (in shares)	'	0	0	315,959	'	'	0
Common stock issued in conversion of redeemable preferred stock and 296,250 warrants	2,362,517	0	0	59	2,362,458	0	0
Common stock issued in conversion of redeemable preferred stock and 296,250 warrants (in shares)	'	0	0	592,500	'	'	0
Common stock issued as incentive shares	2,920,000	0	0	75	2,919,925	0	0
Common stock issued as incentive shares (in shares)	'	0	0	750,000	'	'	0
Conversion of sponsor warrants into common stock	0	0	0	10	-10	0	0
Conversion of sponsor warrants into common stock (in shares)	'	0	0	100,000	'	'	0
Stock issued to underwriters	0	0	0	33	-33	0	0
Stock issued to underwriters (in shares)	'	0	0	335,000	'	'	0
Stock subject to redemption	-8,651,639	8,651,639	0	-84	-8,651,555	0	0
Stock subject to redemption (in shares)	'	839,965	0	-839,965	'	'	0
Expenses of offering	-814,076	0	0	0	-814,076	0	0
Payments to Series A Holders	3,101,038	0	0	0	-3,101,038	0	0
Assumed liabilities of Selway	-6,323,148	0	0	0	-6,323,148	'	'
Recognition of contingent beneficial conversion feature on the convertible bridge notes	1,182,327	0	0	0	1,182,327	'	'
Stock based compensation	283,889	0	0	0	283,889	0	0
Net loss	-14,066,292	0	0	0	0	-14,066,292	0
Ending balance at Jun. 30, 2013	($8,281,522)	$8,651,639	$0	$895	$16,423,417	($24,705,834)	$0
Ending balance (in shares) at Jun. 30, 2013	'	839,965	0	8,953,494	'	'	0

CONSOLIDATED_STATEMENTS_OF_STO1

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT AND REDEEMABLE SECURITIES [Parenthetical] (USD $)	6 Months Ended
	Jun. 30, 2013
Common stock issued in conversion of redeemable preferred stock and warrants	$296,250

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Cash used in operating activities:	'	'
Net loss	($14,066,292)	($7,575,965)
Adjustments to reconcile net loss to cash used in operating activities:	'	'
Depreciation and amortization	156,664	205,997
Non cash interest expense	2,443,296	0
Stock-based compensation	3,683,889	0
Note-based compensation	412,824	0
Common stock issued as other expense	0	641,142
Mark to market adjustment on warrant liability	-62,163	0
Changes in assets and liabilities:	'	'
Accounts receivable	-124,733	42,316
Rebates receivable	-251,185	-1,323,474
Inventory	101,059	-258,296
Prepaid expenses and other current assets	300,811	-603,338
Other assets	21,555	0
Accounts payable and accrued expenses	2,589,957	295,502
Deferred revenues	-142,937	638,223
Other liabilities	153,070	0
Deferred rent	0	16,486
Total cash used in operating activities	-4,784,185	-7,921,407
Cash used in investing activities:	'	'
Purchase of property and equipment	-104,981	-495,768
Total cash used in investing activities	-104,981	-495,768
Cash from financing activities:	'	'
Proceeds from cash received at Merger	11,948,361	0
Payment to Series A Holders	-3,101,038	0
Expense of offering	-814,076	0
Proceeds from sale of common stock	0	9,420
Proceeds from (Payments of) notes payable	-3,025,000	4,192,954
Drawings on line of credit	534,343	0
Debt costs	-527,024	0
Redeemable preferred stock	0	2,362,517
Warrants (repaid)/ issued	0	371,350
Redemption of common stock	0	-100,000
Payments of capital leases	-125,508	0
Other	0	17,683
Total cash provided by financing activities	4,890,058	6,853,924
Net increase (decrease) in cash	892	-1,563,251
Cash, beginning of period	1,791,134	3,354,385
Cash, end of period	1,792,026	1,791,134
Supplemental disclosures:	'	'
Interest	-305,318	-852,276
Income taxes	0	0
Conversion of stockholdersb loans to equity	2,306,501	0
Equipment purchases under capital leases	436,504	'
Deferred financing fees incurred but not paid	88,730	'
Promissory notes and interest converted to common stock	3,159,624	'
Assets received in reverse merger:	'	'
Other receivable	857	40,867
Note receivable	3,554	'
Total receivable	4,411	'
Liabilities assumed in reverse merger:	'	'
Liabilities assumed	6,327,559	'
Net liabilities assumed	6,323,148	'
Warrant Liability [Member]	'	'
Liabilities assumed in reverse merger:	'	'
Liabilities assumed	4,018,000	'
Common Stock [Member]	'	'
Liabilities assumed in reverse merger:	'	'
Liabilities assumed	0	'
Additional Paid-in Capital [Member]	'	'
Liabilities assumed in reverse merger:	'	'
Liabilities assumed	0	'
Accumulated Deficit [Member]	'	'
Liabilities assumed in reverse merger:	'	'
Liabilities assumed	0	'
Notes Payable [Member]	'	'
Liabilities assumed in reverse merger:	'	'
Liabilities assumed	1,977,570	'
Accounts Payable [Member]	'	'
Liabilities assumed in reverse merger:	'	'
Liabilities assumed	183,981	'
Deferred Underwriting Fees [Member]	'	'
Liabilities assumed in reverse merger:	'	'
Liabilities assumed	$148,008	'

Description_of_Business

Description of Business	6 Months Ended
	Jun. 30, 2013
Description Of Organization and Business Operations [Abstract]	'
Description of Organization and Business Operations Disclosure [Text Block]	'
	1	Description of Business
	Selway Capital Acquisition Corporation (“SCAC” or “Selway”) was originally incorporated under the laws of Delaware on January 12, 2011 for the purpose of acquiring one or more operating businesses through merger or capital stock exchange. On January 25, 2013, an agreement and plan of merger (the “Merger”) was entered into between SCAC and Healthcare Corporation of America (“HCCA”). The Merger closed on April 10, 2013 with SCAC being the surviving entity upon the consummation of the Merger (see Note 3).
	HCCA and its wholly-owned subsidiaries, Prescription Corporation of America Benefits (“PCA Benefits”) and Prescription Corporation of America (“PCA”), are engaged in providing benefits management and mail order pharmaceutical fulfillment services to companies primarily in the northeast United States.
	On June 3, 2013, SCAC amended its articles of incorporation to change its name to Healthcare Corporation of America (collectively with its subsidiaries, the “Company”).
	On April 22, 2013, the Company’s board of directors approved the change of its fiscal year end from December 31 to June 30.
	On November 7, 2013, the board of directors approved the change of its fiscal year end back to December 31.
	The accompanying historical consolidated financial statements represent the financial position and results of operations of HCCA through April 10, 2013 and the financial position and results of operations of the Company thereafter  (see Note 3).

Liquidity_and_Financial_Condit

Liquidity and Financial Condition	6 Months Ended
	Jun. 30, 2013
Liquidity and Financial Condition [Abstract]	'
Liquidity and Financial Condition Text block [Text Block]	'
	2	Liquidity and Financial Condition
	The Company has a working capital deficit and a history of recurring losses and negative cash flows from operating activities. As of June 30, 2013 and December 31, 2012, the Company has a working capital deficit of $3,640,546 and $4,564,045, respectively and stockholders’ deficit of $8,281,522 and $3,951,169, respectively. During the six months ended June 30, 2013 and year ended December 31, 2012, the Company incurred net losses of $14,066,292 and $7,575,965, respectively, and negative cash flows from operating activities of $4,784,185 and $7,921,407, respectively. Collectively, these factors raise substantial doubt about the Company’s ability to continue as a going concern.
	The Company is currently making efforts to raise capital in the form of debt and/or equity. No assurance can be given that the debt and/or equity can be raised and if available it will be on terms acceptable to the Company.
	The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

The_Merger

The Merger	6 Months Ended
	Jun. 30, 2013
Business Combinations [Abstract]	'
Merger Disclosure [Text Block]	'
	3	The Merger
	On January 25, 2013, an Agreement and Plan of Merger (the “Agreement”) was entered into by and among the Company, Selway Merger Sub, Inc., a New Jersey corporation and wholly owned subsidiary of the Company (“Merger Sub”), HCCA, PCA, and representatives of HCCA and the Company. On April 10, 2013 (the “Closing Date”), the Merger and other transactions contemplated by the Agreement closed.
	Pursuant to the Agreement, Merger Sub merged with and into HCCA, resulting in HCCA becoming a wholly owned subsidiary of the Company. PCA and PCA Benefits, a dormant entity, remain wholly owned subsidiaries of HCCA.
	Holders of all of the issued and outstanding shares of common stock of HCCA immediately prior to the time of the Merger had each of their shares of common stock of HCCA converted into the right to receive: (i) a proportional amount of 5,200,000 shares of the Company’s Series C common stock and promissory notes with an aggregate face value of $7,500,000 (collectively, the “Closing Payment”); plus (ii) a proportional amount of up to 2,800,000 shares of the Company’s common stock, if any, (the “Earn-out Payment Shares”) issuable upon the Company achieving certain consolidated gross revenue thresholds as more fully described below; plus (iii) the right to receive a proportional amount of the proceeds from the exercise of certain warrants being issued to Selway Capital Holdings, LLC, Selway’s sponsor, as more fully described below. A portion of the Closing Payment (520,000 shares and promissory notes with an aggregate face value of $750,000) was being held in escrow for a period of 12 months following the Merger to satisfy indemnification obligations of HCCA. Effective December 20, 2013, the escrowed portion of the Closing Payment, together with a portion of the shares issued to HCCA’s investment banking advisor (an aggregate of 546,002 shares, and promissory notes with an aggregate face value of $750,000) were released from escrow and cancelled.
	The promissory notes included in the Closing Payment are non-interest bearing and subordinated to all senior debt of the combined company in the event of a default under such senior debt. The notes will be repaid from 18.5% of the Company’s free cash-flow (as defined) in excess of $2,000,000. The Company will be obligated to repay such notes if, among other events, there is a transaction that results in a change of control of the Company. The Company valued the notes at $1,977,570, which represented the present value of the estimated future cash flows to be generated by the combined companies discounted using an interest rate reflective of the uncertainty and credit risk of the notes.
	Certain members of HCCA’s management received an aggregate of 1,500,000 shares of our common stock (the “Management Incentive Shares”), which shares were placed in escrow and subject to release in three installments through June 30, 2015. Subsequently, certain members of HCCA management agreed to cancel an aggregate of 750,000 shares pursuant to rescission agreements entered into June 2013. Of the remaining Management Incentive Shares outstanding, 400,000 shares have vested but remain in escrow until June 30, 2014 and 350,000 shares will vest on June 30, 2015 and will remain in escrow until June 30, 2015.
	As part of the Merger, Selway’s net liabilities, consisting primarily of warrant liabilities, were assumed. As part of its Initial Public Offering, Selway issued 2,000,000 warrants, with an exercise price of $7.50 and an expiration date of November 6, 2016 (“Selway IPO Warrants”). These warrants are classified as liabilities based on certain anti-dilution features. The Selway IPO Warrants were recorded at $4,018,000 based on the closing price of the warrants on the date of Merger.
	The Earn-out Payment Shares, if any, will be issued as follows: (i) 1,400,000 shares if the Company achieves consolidated gross revenue of $150,000,000 for the twelve months ended March 31, 2014 or June 30, 2014; and (ii) 1,400,000 shares if the Company achieves consolidated gross revenue of $300,000,000 for the twelve months ended March 31, 2015 or June 30, 2015. In the event the Company does not achieve the first earn-out threshold, but does achieve the second earn-out threshold, then all of the Earn-out Payment Shares shall be issued. If the Company consolidates, merges or transfers substantially all of its assets prior to June 30, 2015 at a valuation of at least $15.00 per share, then all of the Earn-out Payment Shares not previously paid out shall be issued immediately prior to such transaction. If, prior to achieving either earn-out threshold the Company acquires another business in exchange for its equity or debt securities, then any remaining earn-out thresholds may be adjusted by the independent members of the Company’s board of directors at their sole discretion. The Company estimates that it will not achieve any of the abovementioned revenue targets and, therefore, no provision has been made for the Earn-out Payment Shares.
	The Agreement required 10% of the consideration, or 520,000 shares of the Company’s Series C common stock and promissory notes with a face value of $750,000 to be held in escrow for a period of one year. As a result of the investigation and subsequent restatement (see Note 4), in December 2013 these shares of stock and promissory notes were returned to the Company. Also in December 2013, the rights to additional proceeds from the exercise of certain warrants issued to Selway Capital Holdings, LLC as part of the merger were cancelled.
	In connection with a bridge financing (the “Bridge Financing”) completed by HCCA in September 2012, HCCA issued 59.25 units, each unit consisted of 10,000 Convertible Preferred Shares, a warrant for 5,000 shares of common stock that, upon a merger with Selway, converted to warrants with the same terms as Selway IPO warrants and a Promissory Note with a face value of $100,000  (“Promissory Notes”). At the time of the Merger, holders of all of the issued and outstanding shares of preferred stock of HCCA, by virtue of the Merger, had each of their shares of Preferred Stock of HCCA converted into the right to receive a proportional amount of 592,500 shares of the Company’s Series C common stock and warrants to purchase 296,250 shares of the Company’s Series C common stock. If a Merger with Selway or equivalent, as defined in the Preferred Stockholder agreement, occurred before the maturity date of the promissory notes, the preferred stock converted on a 1 to 1 basis into Series C Common Stock of Selway. If such Merger did not occur, then at the maturity of the Promissory Notes, the Preferred Stock converted into 3.7% of common stock of HCCA on a fully diluted basis. Upon issuing the preferred stock, HCCA determined the contingent beneficial conversion feature to the holders of the Preferred Stock if the Merger with Selway occurred to be $3,532,858 and recorded that as a deemed dividend to the Preferred Stockholders upon the closing of the Merger.
	The warrants issued in connection with the bridge loan were initially exercisable at $7.50 into shares of common stock of HCCA and expired on November 7, 2016. The warrants contained certain anti-dilution that caused them to be classified as liabilities. Upon completion of the Merger with Selway, the warrants became exercisable in Series C shares of Common Stock of Selway. The exercise price and expiration date remained the same.
	The Promissory Notes bore interest at 8%, were convertible into 10,000 shares of Series C Common Stock if a transaction with Selway occurred and matured on the earlier of a transaction with Selway or September 12, 2013. HCCA allocated the value received from the sale of the units first to the estimated fair value of warrants. The residual value was then allocated to the preferred stock and promissory note based on their relative fair values. As a result of the allocation, HCCA recorded a debt discount of $2,445,242. The debt discount was amortized to interest expense over the term of the Promissory Note. HCCA recorded interest expense of $1,732,047, including $1,018,851 to recognize the unamortized debt discount at the transaction date in the period ending June 30, 2013. HCCA recorded interest expense of $713,196 related amortization of the debt discount in the year ended December 31, 2012. Upon issuing the promissory notes, HCCA determined the contingent beneficial conversion feature to the holders of the Promissory Notes, if they converted into shares of Selway and recorded additionally $1,182,327, as additional interest expense upon the conversion of the promissory notes. In accordance with the terms of the promissory notes issued in the Bridge Financing, at the time of the Merger, notes in the aggregate amount of $3,159,624 (including principal and interest accrued to date) were converted into 315,959 shares of the Company’s Series C common stock and notes in the aggregate principal amount of $3,025,000 were repaid in full. The promissory note included in the Bridge Financing was only convertible into shares of common stock if the transaction with Selway closed before the maturity of the note. At the issuance of the Bridge Financing, the Company determined that a contingent beneficial conversion feature existed representing the difference in the value of the underlying shares and the allocated value to the promissory note. Upon closing of the transaction, the Company recognized the contingent beneficial conversion feature and recorded $1,182,327 as additional interest expense in the period ended June 30, 2013.
	In connection with the Bridge Financing, HCCA executed a registration rights agreement that required it to register the shares underlying the Bridge Financing if the transaction was completed. The agreement required HCCA to file a registration statement within 60 days of the completion of the transaction with Selway and have the registration statement declared effective within 120 days. The agreement requires damages of 1% per month of the Bridge Financing, capped at 10%, for each month the Company does not comply with the requirement. As a result of the restatements and investigation, the Company concludes that it is probable it will not file a registration statement and have declared within the period required and estimates that it will incur the maximum damages under the agreement. The Company recorded $592,500 to interest expense for the period ended June 30, 2013.
	In conjunction with the merger of Merger Sub into HCCA:
		·	The Company entered into exchange agreements with three beneficial holders of HCCA’s bridge loan who were also beneficial holders of greater than 5% of the Company’s Series A common stock. Pursuant to the exchange agreements, such holders converted an aggregate of 281,554 shares of the Company’s Series A common stock to the Company’s Series C common stock. In conjunction with the exchange, such holders were repaid bridge notes in the aggregate principal amount of $3,025,000.
		·	The Company entered into exchange agreements with three beneficial holders of greater than 5% of the Company’s Series A common stock. Pursuant to the exchange agreements, such holders converted an aggregate of 878,481 shares of the Company’s Series A common stock to the Company’s Series C common stock and received $3.53 per share of Series A common stock exchanged, or an aggregate of $3,101,038.
		·	An aggregate of $11,948,361 was released from the Company’s trust account, reflecting the number of shares of the Company’s Series A common stock that were converted into the Company’s Series C common stock, of which $237,007 was paid to the underwriters from the Company’s initial public offering. The Company incurred other costs related to the transaction totaling $577,069 and recorded both these costs and the costs paid to the underwriters as a reduction to Additional Paid In Capital.
		·	The placement warrants held by the Company’s founders were converted into the right to receive: (i) an aggregate of 100,000 shares of common stock; and (ii) warrants to purchase an aggregate of 1,000,000 shares of common stock at an exercise price of $10.00 per share. The proceeds from the exercise of the exchange warrants will be paid: (i) 75% to the holders of all of the issued and outstanding shares of common stock of HCCA immediately prior to the time of the merger; and (ii) 25% to certain members of HCCA management. The exchange warrants are only exercisable for cash, may not be exercised on a cashless basis, and must be exercised if the closing price for the combined company’s common stock exceeds $12.00 per share for 20 trading days in any 30-trading-day period. On November 22, 2013, the Company cancelled these warrants and issued a new warrant to purchase 1 million shares of common stock. The replacement warrant was recorded to additional paid in capital. Per the terms of the warrant agreement, the warrant’s initial exercise price was $7.50 per share, subject to adjustment upon the first subsequent financing of the Company. This financing occurred on December 31, 2013 upon which the exercise price of this warrant was adjusted from $7.50 to $1.50. The new warrants do not include the provision to share the exercise proceeds with former shareholders of HCCA or management. The Company will record a charge in the quarter ended December 31, 2013 reflecting the value of the modification to the warrant.
	Pursuant to an engagement letter entered into by HCCA with its investment banking adviser, 5% of all consideration received was owed to the adviser. Accordingly the Company issued 335,000 shares of common stock representing 5% of the common stock and incentive stock, as adjusted, received by HCCA and issued an incentive note of $500,000 representing 5% of the incentive notes issued to HCCA. The present value of the incentive note was recorded to additional paid in capital and is included in liabilities assumed.
	The business combination of the Company and HCCA was accounted for as a reverse recapitalization of HCCA, since prior to the merger the Company was a shell corporation as defined under Rule 12b-2 of the Exchange Act. HCCA was treated as the accounting acquirer in this transaction due to the following factors:
		1)	HCCA’s management pre-closing remained as the management of the Company post-closing;
		2)	The members of the board of directors of HCCA pre-closing represent the majority of directors of the Company post- closing; and
		3)	The majority of shares of the Company post-closing were still owned by HCCA shareholders, who represented 60% of the Company’s shares outstanding immediately after closing, if all shares subject to conversion in our post-closing tender offer actually convert to Series C (non-redeemable) common shares, and 65% of the Company’s shares outstanding if all shares subject to conversion do not convert to Series C shares and opt to receive their pro rata cash in trust at the time of the post-closing tender offer. Estimates of HCCA’s ownership do not include shares underlying warrants held by public investors and the Company’s sponsors restricted incentive shares held by management. However, HCCA shareholders would still have 51% of the Company’s shares post-closing when including shares underlying warrants and restricted shares and assuming all redeemable shares convert to Series C shares, and 54% of the Company’s shares post-closing if all shares subject to conversion do not convert to Series C shares and opt to receive their pro rata cash in trust at the time of the post-closing tender offer.

Restatement

Restatement	6 Months Ended
	Jun. 30, 2013
Restatement [Abstract]	'
Restatement [Text Block]	'
	4	Restatement
	The financial statements for 2012 have been revised to correct material errors in accounting for the Company’s sales, accounts receivable, cost of sales, accounts payable, capital leases, accrued rent and accrued taxes. In accordance with applicable Generally Accepted Accounting Principles (GAAP), the Company calculated and recognized adjustments accordingly.
	On March 25, 2013, the Company filed with the Securities and Exchange Commission (“SEC”) its audited financial statements for the years ended December 31, 2012 and 2011. Following the discovery of various material errors the Company informed the SEC on May 9, 2013 that these financial statements could not be relied upon, and on May 15, 2013 filed its restated audited financial statements for the above-mentioned periods (First Restatement Financial Statements).
	On September 19, 2013 following the discovery by management of additional material errors and misstatements in the First Restatement Financial Statements, the Company informed the SEC that the previously restated financials could not be relied upon and that the Company would review its financial statements in an attempt to discover all the material errors and misstatements that were included therein.
	As part of this review, the Company engaged external consultants to review and investigate its books and records and other related transactions and activities for 2012 and 2011. As a result of this review, management concluded that it will be unable to complete its restated 2011 financial statements, due to lack of sufficient source documents and other information. In addition, the Company discovered various additional material errors and misstatements in the 2012 financial statements which were corrected in these restated financial statements.
	The following table represents the effects of the subsequent and first restated statements as of December 31, 2012:
			Subsequent		First
			Restatement		Restated		Original
			December 31, 2012		December 31, 2012		December 31, 2012
	Accounts receivable		$	1,126,846	$	572,637	$	1,220,065
	Rebates receivable		$	1,323,474	$	1,323,474	$	1,638,000
	Other receivables		$	40,867	$	40,867	$	40,867
	Accounts payable		$	4,431,366	$	4,520,223	$	1,514,857
	Accrued expenses		$	568,528	$	453,057	$	453,057
	Note payable		$	4,192,954	$	4,947,613	$	4,947,613
	Redeemable preferred stock		$	2,362,517	$	458,800	$	458,800
	Warrant liability		$	121,350	$	518,587	$	518,587
	Common stock		$	4,175,856	$	3,556,056	$	3,556,056
	APIC		$	150,000	$	-	$	-
	Sales		$	27,305,795	$	28,663,284	$	38,401,140
	Cost of sales		$	26,148,118	$	24,068,906	$	31,650,232
	General and administrative expenses		$	7,603,458	$	7,299,603	$	7,299,603
	Interest expense		$	-1,130,184	$	640,286	$	640,286
	Accumulated deficit		$	-10,639,542	$	-8,937,860	$	-4,970,540
	Loss per share		$	-0.19	$	-0.09	$	-0.02

Significant_Accounting_Policie

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	5	Significant Accounting Policies
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements including disclosure of contingent assets and liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company’s critical accounting policies are those that are both most important to the Company’s financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results could differ from these estimates.
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.
	Accounts Receivable
	Accounts receivable represent amounts owed to the Company for products sold and services rendered net of an allowance for doubtful accounts. The Company grants unsecured credit to its customers. The Company continuously monitors the payment performance of its customers to ensure collections and minimize losses. Management does not believe that significant credit risks exist. An allowance for doubtful accounts is based upon the credit profiles of specific customers, economic and industry trends and historic payment experience. There is no allowance for doubtful accounts at June 30, 2013 and December 31, 2012.
	Inventory
	Inventories consist of finished pharmaceutical products and are recorded at the lower of cost or market, with the cost determined on a first-in, first-out basis. The Company periodically reviews the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the decline in values is first recognized.
	Rebates
	Pharmaceutical manufacturers offer rebates for selected brand drugs. The Company currently receives these rebates through a third party administrator. The rebates are considered earned when members (employees of customers) order the drugs. Rebates earned are paid to the Company by the third party administrator quarterly. Rebates earned are recognized as a reduction to cost of revenue. The portion of the rebate payable to customers is simultaneously recognized as a reduction of revenue. Management evaluates rebates receivable at the end of every reporting period and adjusts the amount reflected on the accompanying balance sheet to net realizable value. An adjustment is also made to the rebate payable to customers to correspond with any adjustment that applies to rebates receivable.
	Property and Equipment
	Property and equipment are stated at cost less accumulated amortization and depreciation. Leasehold improvements are amortized using the straight-line method over the shorter of the term of the lease or the estimated useful lives of the assets. Furniture and fixtures are depreciated using the straight-line method over the estimated useful lives of the assets of 5 years. Computer equipment and software are depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 5 years.
	Internal-Use Software Development Costs
	The Company capitalizes certain costs associated with the purchase and/or development of internal-use software, including its website. Generally, external and internal costs incurred during the application development stage of a project are capitalized. The application development stage of a project generally includes software design and configuration, coding, testing and installation activities. Training and maintenance costs are expensed as incurred. Upgrades and enhancements are capitalized if it is probable that such expenditures will result in additional functionality. Capitalized software costs are amortized using the straight-line method over the estimated useful life of the asst, which approximates 3 years.
	Long-Lived Assets
	Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Company assesses recoverability by determining whether the net book value of the related asset will be recovered through the projected undiscounted future cash flows of the asset. If the Company determines that the carrying value of the asset may not be recoverable, it measures any impairment based on the fair value of the asset as compared to its carrying value. During the six months ended June 30, 2013 and the year ended December 31, 2012, the Company did not record any impairment charges.
	Investments Held in Trust
	The Company applies the provisions of ASC Topic 320-10, Investment – Debt and Equity, to account for investments held in trust, which comprise only of held-to maturity securities. Held-to-maturity securities are those securities, which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost on the accompanying balance sheets and adjusted for any amortization or accretion of premiums or discounts.
	Deferred Financing Costs
	Costs relating to obtaining the line of credit in April 2013 and the Bridge Notes in September 2012 have been capitalized and amortized over the term of the related debt using the straight line method. Amortization of deferred financing costs charged to interest expense was $686,631 and $254,993 in the six months ended June 30, 2013 and for the year ended December 31, 2013, respectively. The unamortized balance was $548,394 and $552,380 at June 30, 2013 and December 31, 2012, respectively.
	Derivative Financial Instruments
	The Company applies the provisions of ASC Topic 815-40, Contracts in Entity’s Own Equity (“ASC Topic 815-40”), under which convertible instruments and warrants, which contain terms that protect holders from declines in the stock price (reset provisions), may not be exempt from derivative accounting treatment. As a result, such warrants are recorded as a liability and are revalued at fair value at the end of each reporting period. Furthermore, under derivative accounting, the warrants are initially recorded at their fair value. If the fair value of the warrants exceeds the face value of the related debt, the excess is recorded as a change in fair value in the statement of operations on the issuance date.
	Debt Discounts
	Debt discounts are amortized using the effective interest rate method over the term of the related debt. The result achieved using the straight-line method is not materially different than those which would result using the effective interest method.
	Share-Based Payments
	Share-based payments to employees are measured at the fair value of the award on the date of grant based on the estimated number of awards that are ultimately expected to vest. The compensation expense resulting from such awards is recorded over the vesting period of the award in selling, general and administrative expenses on the accompanying consolidated statements of operations.
	Share-based payments to non-employees for services rendered are recorded at either the fair value of the services rendered, or the fair value of the awards, whichever is more readily determinable. The expense resulting from such awards is  marked to market over the vesting period of the award in selling, general and administration expenses on the accompanying consolidated statements of operations.
	Revenue Recognition
	The Company typically enters into annual renewable agreements with its customers to provide pharmacy benefit management on a fixed price or self-insured basis. The Company records revenues from all its current contracts with customers gross as the Company acts as principal based on the following factors: 1) the Company has a separate contractual relationship with its customers and with its claims adjudicator to whom the Company pays the costs of the prescription drugs consumed by its customers (the claims), 2) the Company through its claim adjudicator is responsible to validate and manage the claims, and 3) the Company bears the credit risk for the amount due from the customers. Revenues are recorded monthly as earned. The Company also operates a mail order pharmacy that services plan members. All revenues and associated costs from dispensing drugs by the mail order pharmacy to our plan members, excluding the members’ co-pay are eliminated as inter-company revenues. Some of the contracts contain terms whereby the Company makes certain financial guarantees regarding prescription costs. Actual performance is compared to the guaranteed measure throughout the period and accruals are recorded as an offset to revenue if the Company fails to meet a financial guarantee.
	Cost of Sales
	Cost of sales includes claim payments for both fixed- price and self-insured programs, administrative fees paid for processing the claims to the claims adjudicator and, the cost of prescription drugs of the mail order pharmacy.
	Advertising Expenses
	Advertising expenses are expensed as incurred and included in selling, general and administrative expenses on the accompanying statements of operations. Advertising expenses were approximately $68,000 and $143,000 for the six months ended June 30, 2013 and year ended December 31, 2012, respectively.
	Income Taxes
	The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is established when realization of net deferred tax assets is not considered more likely than not.
	Uncertain income tax positions are determined based upon the likelihood of the positions being sustained upon examination by taxing authorities. The benefit of a tax position is recognized in the consolidated financial statements in the period during which management believes it is more likely than not that the position will not be sustained. Income tax positions taken are not offset or aggregated with other positions. Income tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of income tax benefit that is more than 50 percent likely of being realized if challenged by the applicable taxing authority. The portion of the benefits associated with income tax positions taken that exceeds the amount measured is reflected as income taxes payable.
	The Company recognizes interest related to uncertain tax positions in interest expense. The Company recognizes penalties related to uncertain tax positions in income tax expense.
	Fair Value Measurements
	The Company applies recurring fair value measurements to its derivative instruments in accordance with ASC 820, Fair Value Measurements. In determining fair value, the Company uses a market approach and incorporates assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation techniques. These inputs can be readily observable, market corroborated or generally unobservable internally-developed inputs. Based upon the observability of the inputs used in these valuation techniques, the Company’s derivative instruments are classified as follows:
		Level 1:	The fair value of derivative instruments classified as Level 1 is determined by unadjusted quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date.
		Level 2:	The fair value of derivative instruments classified as Level 2 is determined by quoted market prices for similar assets or liabilities in active markets, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data.
		Level 3:	The fair value of derivative instruments classified as Level 3 is determined by internally-developed models and methodologies utilizing significant inputs that are generally less readily observable from objective sources.
	The Company’s valuation methodology for warrants classified as derivative liabilities qualifies as a level 2 fair value measurement since it is determined using internally developed models and analysis.
	At June 30, 2013 the Company had 2,000,000 warrants exercisable into its Class C shares that were issued in connection with Selway’s initial public offering (“Selway IPO Warrants”). These warrants are publicly traded and are classified as liabilities. Additionally, HCCA issued 296,250 warrants in connection with the Bridge Financing with identical terms as the Selway IPO Warrants. The Company has valued all of these warrants as June 30, 2013 based on the closing price of the Selway IPO Warrants. Because the market for the Selway IPO Warrants is not active, the valuation is classified as a Level 2 measurement. These warrants are exercisable at $7.50 a share and expire on November 7, 2016.
	The table below presents the Company’s fair value hierarchy for those derivative instruments measured at fair value on a recurring basis as of June 30, 2013:
			Level 1		Level 2		Level 3		Total
	Warrants		$	-	$	3,559,188	$	-	$	3,559,188
	Total derivative liabilities		$	-	$	3,559,188	$	-	$	3,559,188
	The table below presents the Company’s fair value hierarchy for those derivative instruments measured at fair value on a recurring basis as of December 31, 2012:
			Level 1		Level 2		Level 3		Total
	Warrants		$	-	$	121,350	$	-	$	121,350
	Total derivative liabilities		$	-	$	121,350	$	-	$	121,350
	Fair Value of Financial Instruments
	The fair values of cash and cash equivalents, accounts receivable, rebates receivable and accounts payable approximate their carrying values due to the short-term nature of the instruments. The fair values of long-term debt and revolving loans approximates their carrying value due to their variable interest rates. The fair value of investments held in trust is not materially different than its carrying value because of the short-term nature of the investments.
	Risks and Concentrations
	The Company utilizes the services of a single claims adjudicator. If there is an adverse situation in this relationship, the Company’s mail order pharmaceutical fulfillment services would be ineffective until a replacement claims adjudicator was obtained.
	Approximately 12% of the Company’s 2012 revenues were derived from one customer. Revenues from this customer were 10% of our revenues for the six month period ended June 30, 2013. No amounts were due from this customer at June 30, 2013 or December 31, 2012. In addition, one of the reseller’s customers accounted for approximately 14% of the Company’s revenue for the six month period ended June 30, 2013 as well as approximately 14% of the Company’s revenue for the year ended December 31, 2012. Amounts due from this customer represented 32% and 46% of accounts receivable at June 30, 2013 and December 31, 2012, respectively.
	Cash and Cash Equivalents
	The Company considers all cash in bank, money market funds and certificates of deposit with an original maturity of less than three months to be cash equivalents. The Company maintains its cash and cash equivalents in one financial institution. Cash balances on hand at this financial institution may exceed the insurance coverage provided to the Company by the Federal Deposit Insurance Corporation at various times during the year.
	Earnings (Loss) Per Share
Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share are determined in the same manner as basic earnings (loss) per share, except that the number of shares is increased to include potentially dilutive securities using the treasury stock method. Because the Company incurred a net loss in all periods presented, all potentially dilutive securities were excluded from the computation of diluted loss per share because the effect of including them is anti-dilutive.
		Six Months Ended		Year Ended
		June 30, 2013		December 31, 2012
Basic and Diluted:
Net loss		$	-14,066,292	$	-7,575,965
Less: Deemed dividend to preferred stockholders			-3,532,858		-
Net loss attributable to common stockholders		$	-17,599,150	$	-7,575,965
Weighted average shares			6,851,819		38,939,909
Basic loss per common share		$	-2.57	$	-0.19
The following table summarizes the number of shares of common stock attributable to potentially dilutive securities outstanding for each of the periods which are excluded in the calculation of diluted loss per share:
		Six Months Ended		Year Ended
		June 30, 2013		December 31, 2012
Dilutive Potential Common Shares
Warrants		$	3,314,023	$	1,585,833
Restricted stock awards			-		75,292
Convertible notes payable			-		2,666,667
Reclassification
Certain previously reported amounts have been reclassified to conform to the presentation used in the June 30, 2013 financial statements.

Property_and_Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	6	Property and Equipment
	Property and equipment is as follows:
			June 30, 2013		December 31, 2012
	Furniture, fixtures and equipment		$	1,606,404	$	1,374,126
	Leasehold improvements			25,260		10,162
				1,631,664		1,384,288
	Accumulated depreciation and amortization			-394,930		-270,233
	Net property and equipment		$	1,236,734	$	1,114,055
	Amortization and depreciation is approximately $124,700 and $206,000 for the six months ended June 30, 2013 and 2012.

Software_net

Software, net	6 Months Ended
	Jun. 30, 2013
Capitalized Computer Software, Net [Abstract]	'
Research, Development, and Computer Software Disclosure [Text Block]	'
	7	Software, net
	Software, net is as follows:
			June 30, 2013		December 31, 2012
	Software costs		$	294,109	$	-
	Accumulated amortization			-31,967		-
	Net software costs		$	262,142	$	-
	Amortization expense was approximately $32,000 for the six month period ended June 30, 2013.

Investments_Held_in_Trust

Investments Held in Trust	6 Months Ended
	Jun. 30, 2013
Investment Held In Trust [Abstract]	'
Investment [Text Block]	'
	8	Investments Held in Trust
	Following the initial public offering (“IPO”) of Selway in November 2011, a total of $20.6 million was placed in a trust account maintained by American Stock Transfer & Trust Company, as trustee. None of the funds held in the trust were to be released from the trust account, other than interest income, net of taxes, until the earlier of (i) consummation of an acquisition and (ii) redemption of 100% of the public shares sold in the IPO if Selway failed to consummate an acquisition by May 14, 2013.
	On April 10, 2013, Selway closed the acquisition of HCCA through the Merger (see Notes 1 and 3). At the time of the Merger, holders of 1,160,035 shares of redeemable common stock decided not to redeem their shares and accordingly approximately $11,948,000 was released from the escrow. As per the certificate of incorporation of Selway, the remaining balance of the trust account of approximately $8,652,000 was used to redeem the remaining 839,965 redeemable common shares through a tender offer which closed on August 15, 2013. The amount in trust can be invested only in United States “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act of 1940 having a maturity of 180 days or less. During the six months ended June 30, 2013, the United States government securities were in an account at Wells Fargo Bank, while the cash amount was in a JP Morgan Chase cash account. The United States government securities matured and the total trust balance of $8,652,482 was in cash.
	The Company classified its United States Treasury and equivalent securities as held-to-maturity in accordance with FASB ASC 320, “Investments – Debt and Equity Securities.” Held-to-maturity treasury securities are recorded at amortized cost on the accompanying balance sheet and adjusted for the amortization or accretion of premiums or discounts.

Deferred_Financing_Costs

Deferred Financing Costs	6 Months Ended
	Jun. 30, 2013
Deferred Finance Costs [Abstract]	'
Deferred Financing Cost [Text Block]	'
	9	Deferred Financing Costs
	Deferred financing costs are as follows:
	Balance January 1, 2013		$	-
	Costs incurred for line of credit for the six months ended June 30, 2013			615,754
	Amortization for the six monthes ended June 30, 2013			-67,360
	Balance June 30, 2013		$	548,394

Accrued_Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	10	Accrued Expenses
	Accrued expenses are as follows:
			June 30, 2013		December 31, 2012
	Accrued severence costs*		$	750,000	$	-
	Accrued rebates			364,196		77,329
	Accrued registration rights penalties**			592,000		-
	Accrued professional fees			290,777		50,000
	Accrued expenses other			431,060		441,199
			$	2,428,033	$	568,528
		*	Payable to a former executive of the Company.
		**	Estimated penalties relating to late registration of shares of common stock in connection with the bridge notes.

Line_of_Credit

Line of Credit	6 Months Ended
	Jun. 30, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	11	Line of Credit
	On April 11, 2013, the wholly-owned subsidiaries of HCCA, entered into a credit and security agreement for a secured revolving credit facility with an initial aggregate credit limit of $5,000,000. The facility has a term of 3 years, through April 11, 2016, during which the loan proceeds are to be used solely for working capital. The facility was terminated in September 2013 due to the Company’s inability to meet certain financial covenants and all outstanding balances under the line were repaid. The outstanding amount on the line of credit as of June 30, 2013 was $534,343.

Bridge_Notes

Bridge Notes	6 Months Ended
	Jun. 30, 2013
Disclosure Of Bridge Notes [Abstract]	'
Disclosure Of Bridge Notes [Text Block]	'
	12	Bridge Notes
	On September 12, 2012, the Company completed a bridge financing (the “Bridge Financing”) consisting of 59.25 units, each unit consisting of 10,000 preferred shares, 5,000 warrants and a promissory note with a face value of $100,000. At the time of the transaction, the value of the units was allocated as follows: Preferred Stock was recorded at a value of $2,362,517, the warrants were recorded as a warrant liability of $82,726 and the notes were recorded at a value of $3,479,757, reflecting a loan discount of $2,445,242. In addition, the Company incurred loan fees amounting to $673,229. The Company recorded interest expense associated with the amortization of the loan discount and the loan fees through the Merger date.
	At the time of the Merger, holders of all of the issued and outstanding shares of preferred stock of HCCA, by virtue of the Merger, had each of their shares of preferred stock of HCCA converted into the right to receive a proportional amount of 592,500 shares of the Company’s Series C common stock and warrants to purchase 296,250 shares of the Company’s Series C common stock. In accordance with the terms of the promissory notes issued in the Bridge Financing, at the time of the Merger, notes in the aggregate amount of $3,159,592 (including principal and interest accrued to date) were converted into 315,959 shares of the Company’s Series C common stock and notes in the aggregate principal amount of $3,025,000 were repaid in full.

LongTerm_Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2013
Long-term Debt and Capital Lease Obligations, Current [Abstract]	'
Long-term Debt [Text Block]	'
	13	Long-Term Debt
	Incentive Notes
	Upon consummation of the merger (see Note 3), Holders of all of the issued and outstanding shares of common stock of HCCA immediately prior to the time of the Merger had each of their shares of common stock of HCCA converted into the right to receive a proportional amount of 5,200,000 shares of the Company’s Series C common stock and promissory notes with an aggregate face value of $7,500,000 (collectively, the “Closing Payment”).
	In addition, the Company issued to its management $2,500,000 of Management Incentive Notes and paid fees in connection with the transaction by issuing promissory notes having an aggregate principal amount of $500,000, which reflects five percent of all promissory notes issued in the transaction.
	The above described notes with an aggregate face value of $10,500,000 have identical terms and conditions, are non-interest bearing and are subordinated to all senior debt of the Company in the event of a default under such senior debt. The notes will be repaid from 25% of the Company’s free cash-flow (defined as in the notes) in excess of $2,000,000. The Company will be obligated to repay such notes if, among other events, there is a transaction that results in a change of control of the Company.
	The notes were recorded at their estimated present value, based on the estimated time of repayment discounted to the balance sheet date. The Company will continue to re-evaluate its estimates on a periodic basis and adjust the present value of the notes accordingly. Of the Management Incentive Notes, $222,477, net of discount vested immediately and $395,514 is being recognized as management incentive compensation over the estimated payment periods.
			June 30, 2013
	Shareholder notes		$	7,500,000
	Placement notes			500,000
	Management incentive notes			2,500,000
				10,500,000
	Less debt discount			-7,728,486
			$	2,771,514
	Future maturities of the Incentive Notes based on the Company’s estimates are as follows:
	June 30,
	2014		$	-
	2015			-
	2016			399,000
	2017			1,789,000
	2018			3,622,000
	Thereafter			4,690,000
			$	10,500,000
	Capital Leases
	The Company has entered into capital lease agreements for equipment, which expire at various dates through November 2019. The assets capitalized under these leases and associated accumulated depreciation at June 30, 2013 and December 31, 2012 are as follows:
			June 30, 2013		December 31, 2012
	Furniture and equipment		$	1,007,735	$	584,638
	Accumulated depreciation			-250,821		-153,937
			$	756,914	$	430,701
	Amortization of capital leases is included in depreciation expense.
	Minimum future lease payments under capital lease obligations as of June 30, 2013 are as follows:
	Year Ended June 30,
	2014		$	256,257
	2015			242,040
	2016			209,938
	2017			158,814
	2018			106,617
	Thereafter			50,640
	Total future minimum lease payments			1,024,306
	Less amount representing interest			-176,225
	Present value of net minimum lease payments			848,081
	Less current portion			-189,989
			$	658,092

Redeemable_Securities

Redeemable Securities	6 Months Ended
	Dec. 31, 2013
Redeemable Securities [Abstract]	'
Disclosure Of Redeemable Securities [Text Block]	'
	14	Redeemable Securities
	Redeemable common stockholders are entitled to redeem all or a portion of such shares in connection with the Company’s initial Business Transaction, as defined in the Company’s Certificate of Incorporation, and are entitled to share ratably in the trust account, including the deferred underwriting discounts and commissions and accrued but undistributed interest, net of (i) taxes payable, (ii) interest income earned on the trust account (approximately $10.30 per share) and (iii) a pro rata share of the trust account released to the Company for each Share converted to a Series C Share upon completion of a Business Transaction. As of June 30, 2013, there were 839,965 shares of Series B common stock outstanding which are subject to redemption. These shares were redeemed from the trust account on August 15, 2013

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2013
Stockholders Equity Note [Abstract]	'
Stockholders Equity Note Disclosure [Text Block]	'
	15	Stockholders’ Equity
	The Company is authorized 30,000,000 shares of common stock, par value $.0001, which shares may, but are not required to, be designated as part of one of three series, callable Series A, callable Series B and Series C shares. The holders of all common shares shall possess all voting power and each share shall have one vote.
	Series A – Holders of shares of Series A Common Stock are entitled to cause the Corporation to redeem all or a portion of their shares in connection with an acquisition transaction. If the holders of Series A Common Stock do not elect to have their shares redeemed, then they will automatically be converted to Series B Common Stock. As of June 30, 2013 there are no outstanding Series A Common Stock.
	Series B – Holders of shares of Series B Common Stock have the same rights as Series A Common Stock, except Series B Common Stock cannot be issued until such time as all outstanding shares of Series A Common Stock are converted to Series B Common Stock. The holders of Series B Common Stock have the right to participate in a Post-Acquisition Tender Offer or Post-Acquisition Automatic Trust Liquidation. As of June 30, 2013 there are 839,965 shares of Series B Common Stock outstanding, which are accounted for as shares subject to redemption on the balance sheet.
	Series C – Holders of shares of Series C Common Stock have the same rights as Series A Common Stock, except holders of Series C Common Stock are not entitled to (1) cause the Corporation to redeem all or a portion of such Series C Common Stock in connection with the Acquisition Transaction, (2) share ratably in the Trust Account or (3) participate in a Post-Acquisition Tender Offer or Post-Acquisition Automatic Trust Liquidation. As of June 30, 2013, there are 8,953,494 shares of Series C Common Stock outstanding.
	The Series A Common Stock, Series B Common Stock and Series C Common Stock will be automatically consolidated into one series of Common Stock after the consummation of the Post-Acquisition Tender Offer or Post-Acquisition Automatic Trust Liquidation. The consolidation shall be on a one-for-one basis of the then outstanding shares of each series of common stock. Following the automatic consolidation, only one series of Common Stock will be authorized, which will be referred to as “Common Stock,” which occurred after June 30, 2013.
	Prior to the merger the Company’s operations were conducted under the HCCA corporate entity (See Note 1). HCCA had authorized 50,000,000 shares of common stock, no par value. Upon the merger, every 7.6923 HCCA shares of common stock were exchanged into 1 share of the Company’s common stock.
	During 2012, the Company issued 2,120,200 shares of common stock with a fair value range of $0.01 to $0.31. These shares are freely tradable.
	During 2012, the Company settled a suit with a shareholder to repurchase 500,000 shares of its common stock. These shares were recorded as a stock redemption for $100,000 and the shares were received in February 2013. In February 2013, these shares were issued to employees in recognition of service performed and an expense of $480,000 was recorded representing the estimate fair value of the shares issued.
	As part of the Merger, 750,000 restricted shares of stock were issued to certain members of management. The shares were valued at $7.30, the share price at the date of the merger. 400,000 shares vested immediately and the remaining vest through June 30, 2015. In the period ending June 30, 2013, the Company recorded an expense of $2,920,000 for the shares that vested on the date of the Merger and $283,889 for the shares that vest through June 30, 2015.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	16	Income Taxes
	There was no provision (benefit) for income taxes for the six months and year ended June 30, 2013 and December 31, 2012.
	Deferred tax assets are as follows:
			June 30, 2013		December 31, 2012
	Loss carryforwards		$	6,363,018	$	2,064,222
	Intangible assets			81,000		44,000
	Accrued expenses			1,060,000		1,060,000
	Stock based compensation			209,904		-
	Fixed assets			7,409		-14,120
	Less valuation allowance			-7,721,331		-3,154,102
	Total net deferred tax assets		$	-	$	-
	The valuation allowance was increased by $4,567,229 during the six months ended June 30, 2013 and $2,575,828 for the year ended December 31, 2012. The valuation allowance was increased due to uncertainties as to the Company’s ability to generate sufficient taxable income to utilize the net operating loss carry forwards and other deferred income tax items.
	A reconciliation of income taxes at the U.S. federal statutory rate to the income expense is as follows:
			Six Months and Year Ended
			June 30, 2013		December 31, 2012
	U.S. Federal statutory rate		-34	%	-34	%
	State income taxes, net of federal benefit		-5.9		-5.9
	Permanent differences		-0.2		0.2
	Interest expense		7.9		-
	Change in valuation allowance		32.2	%	39.7	%
	Effective tax rate		-	%	-	%
	The Company’s ability to utilize the net operating loss carry forwards in future years may be significantly limited in accordance with the provisions of Section 382 of the Internal Revenue Code, because of the changes in ownership that have occurred. The Company’s NOL may be further limited should there be any further changes in ownership. As defined in Section 382 of the Internal Revenue Code, the Company who has undergone, or may undergo in the future, a greater than fifty percent ownership change as a result of financing initiatives. Consequently, there may be limitations on the amount of the Company’s NOLs which may be utilized to offset future taxable income in any one year.
	At June 30, 2013, the Company had federal and state net operating loss carry forwards (“NOLs”) of approximately $15,900,000. The federal net operating loss carry forwards will begin to expire in the year 2035.
	In July 2006, the Financial Accounting Standards Board (“FASB”) issued ASC 740-10, Uncertainty in Income Taxes, which defines the threshold for recognizing the benefits of tax-return positions in the financial statements as “more-likely-than-not” to be sustained by the taxing authorities. This statement also requires explicit disclosure requirements about a Company’s uncertainties related to their income tax position, including a detailed roll forward or tax benefits taken that do not qualify for financial statement recognition. The Company files income tax returns in the U.S. federal jurisdiction and New Jersey. The Company’s tax years open to examination for federal and state are from 2009. The Company has no amount recorded for any unrecognized tax benefits as of June 30, 2013 and December 31, 2012 nor did the Company record any amount for the implementation of ASC 740-10-25. The Company’s policy is to record estimated interest and penalty related to the underpayment of income taxes for unrecognized tax benefits as a component of its income tax provision. During the period ended June 30, 2013 and year ended December 31, 2012 the Company did not recognize any interest or penalties accrued for unrecognized tax benefits.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	17	Commitments and Contingencies
	Operating Leases
	The Company has certain non-cancelable operating leases for facilities and equipment that expire over the next four years. Future minimum payments for non-cancelable operating leases are as follows as of June 30, 2013:
	Minimum Rental Payments
	2014		$	207,764
	2015			206,251
	2016			217,740
	2017			146,520
			$	778,275
	Rent expense for the six months ended June 30, 2013 and for the year ended December 31, 2012 was $96,468 and $186,733, respectively.
	Employment Agreements
	As of June 30, 2013, the Company had entered into employment agreements with senior officers and other members of management. The agreements specify aggregate guaranteed annual salaries of $2.4 million for each year of employment and extended through May 2017. The agreements allowed the Company to terminate these individuals for cause and not for cause. Depending on the terms of the individual contract upon termination without cause the Company would either be required to continue to pay salary through the original term of the contract or pay severance, typically one year of salary.
	From September 2013 to January 2014, the Company terminated agreements representing $1 million in annual compensation. The Company made severance payments of $120,000 and in one case replaced an existing agreement with an annual consulting agreement that renews annually and permits the Company to terminate at any time with 90 days notice.
	As of June 30, 2013, the Company entered into employment contracts or employment arrangement letters with certain members of management that among other things committed the Company to issuing approximately 650,000 stock options. Subsequent to June 30, 2013, the Company entered into additional arrangements committing to issue an additional 841,000 of stock options. The Company does not currently have a stock option plan and these stock options will be granted at the time the stock option plan is appropriately established.
	Litigation
	During 2012, the Company filed a lawsuit against its past adjudicator of claims for overcharges, over payment on claims, errors and misclassifications, and rebates owed from drug manufacturers claiming damages of over $5 million. Additionally, the Company has recorded an expense for the amount owed for claims payable. The adjudicator of claims filed a counterclaim for amounts it claims are owed to it by the Company.
	In August 2013, the Company settled the suit with the claims adjudicator. Under the terms of the settlement the Company agreed to pay the claims adjudicator $2.7 million over 15 months commencing in September 2013. This amount was recorded as a liability as of December 31, 2012, in accounts payable.
	On August 14, 2012, the Company entered into an agreement with a shareholder to buy back 500,000 shares of common stock for $100,000. The order also called upon the payment of $50,000 in legal fees. As of December 31, 2012, the Company had not received the 500,000 shares of common stock but had paid the settlement. The Company received these shares in February 2013. A stock redemption was recorded on December 31, 2012 in the amount of $100,000.

Selected_Financial_Data_unaudi

Selected Financial Data (unaudited)	6 Months Ended
	Jun. 30, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information [Text Block]	'
	18	Selected Financial Data (unaudited)
			Six months ended
			June 30, 2012
	Revenue		$	10,056,735
	Gross profit		$	426,730
	Loss before income taxes		$	-2,490,381
	Net loss		$	-2,495,461
	Basic and diluted net income per share		$	-0.07
	Weighted average number of shares outstanding			37,897,909

Related_Party

Related Party	6 Months Ended
	Jun. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	19	Related Party
	Otis Fund, a company controlled by a former consultant, who owns in excess of 5% of the Company’s outstanding shares, has a consulting agreement to provide marketing and sales services to HCCA. The contract was due to expire on January 2, 2017; however the Company terminated the agreement for cause in September 2013. The annual fees related to these services were $360,000.
	In September 2012, 2,068,200 shares were issued to two entities believed to be controlled by this former consultant of the Company. The Company is currently investigating the circumstances under which these shares were issued to the two entities. The Company recorded a charge in 2012 equal to the shares of $641,142 as general and administrative expense.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	20	Subsequent Events
	On July 15, 2013, the Company entered into a $5 million Loan agreement with Partners For Growth III LP (“PFG”). On October 15, 2013 PFG notified the Company of events of Default. On December 31, 2013, the Company and PFG entered into a forbearance waiver and modification agreement to the Loan agreement.
	The Company issued a total of 555,000 warrants to PFG in connection with the loan agreement and the forbearance waiver and modification agreement.
	On August 15, 2013, the Company completed the purchase, through a tender offer, of 839,965 Series B shares of Common Stock in consideration for approximately $8.65 million (see Notes 8 and 14). Upon the completion of the tender offer and pursuant to the Company’s certificate of incorporation, all three classes of common stock A, B and C were consolidated into one class of common stock.
	On September 26, 2013, the Company terminated its line of credit.
	On November 7, 2013, the Company’s Board of Directors decided to change the Company’s fiscal year end from June 30 to December 31.
	On December 31, 2013, the Company entered into a securities purchase agreement (the “SPA”) with certain purchasers (each a “Purchaser” and collectively, the “Purchasers”) named therein and Chardan Capital Markets, LLC (“Agent”) as administrative and collateral agent. Pursuant to the SPA, the Company issued $2,112,500 of Junior Secured Convertible Term Notes (the “Notes”), which Notes are convertible into shares of the Company’s common stock at an initial fixed conversion price equal to $1.50 per share. The Purchasers of Notes also received warrants (the “Warrants”) to purchase one share for every $1.50 of Notes purchased by such Purchaser. The Company completed the initial closing of a private placement of Notes and Warrants under the SPA on December 31, 2013, and may continue to make subsequent placements under the SPA until it has placed an aggregate of $6,000,000 in Notes under the SPA or the date that is 30 days after the date of such initial closing (the private placements under the SPA are collectively referred to as the “Private Placement”).
	In connection with the Private Placement the Company agreed to pay the Agent a fee representing 9% of the principal amount of the Notes plus the $500,000 additional loan from the Lender, less $250,000, or $2,362,500. The fee was paid in the form of additional Notes (with a pro rata number of warrants) in the amount of $212,625 (for total principal amount of Notes equal to $2,325,125).
	In connection with the issuance of the Notes under the SPA, the Company issued warrants to purchase an aggregate of 1,550,083 shares of common stock (including warrants to purchase 141,750 shares issued to the Agent for its fees), at an exercise price of $3.00 per share (the “Exercise Price”), at any time on or prior to December 31, 2018 (the “Warrants”). The Warrants may also be exercised on a cashless basis.
	The Company and its subsidiaries entered into a Master Security Agreement with the Agent pursuant to which the Company and its subsidiaries agreed to secure the payment of all obligations under the Notes by granting and pledging to the Agent a continuing security interest in all of the Company’s and its subsidiaries’ property now owned or at any time hereafter acquired by them.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements including disclosure of contingent assets and liabilities, at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company’s critical accounting policies are those that are both most important to the Company’s financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results could differ from these estimates.
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances have been eliminated in consolidation.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	'
	Accounts Receivable
	Accounts receivable represent amounts owed to the Company for products sold and services rendered net of an allowance for doubtful accounts. The Company grants unsecured credit to its customers. The Company continuously monitors the payment performance of its customers to ensure collections and minimize losses. Management does not believe that significant credit risks exist. An allowance for doubtful accounts is based upon the credit profiles of specific customers, economic and industry trends and historic payment experience. There is no allowance for doubtful accounts at June 30, 2013 and December 31, 2012.
Inventory, Policy [Policy Text Block]	'
	Inventory
	Inventories consist of finished pharmaceutical products and are recorded at the lower of cost or market, with the cost determined on a first-in, first-out basis. The Company periodically reviews the composition of inventory in order to identify obsolete, slow-moving or otherwise non-saleable items. If non-saleable items are observed and there are no alternate uses for the inventory, the Company will record a write-down to net realizable value in the period that the decline in values is first recognized.
Rebates Policy [Policy Text Block]	'
	Rebates
	Pharmaceutical manufacturers offer rebates for selected brand drugs. The Company currently receives these rebates through a third party administrator. The rebates are considered earned when members (employees of customers) order the drugs. Rebates earned are paid to the Company by the third party administrator quarterly. Rebates earned are recognized as a reduction to cost of revenue. The portion of the rebate payable to customers is simultaneously recognized as a reduction of revenue. Management evaluates rebates receivable at the end of every reporting period and adjusts the amount reflected on the accompanying balance sheet to net realizable value. An adjustment is also made to the rebate payable to customers to correspond with any adjustment that applies to rebates receivable.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment are stated at cost less accumulated amortization and depreciation. Leasehold improvements are amortized using the straight-line method over the shorter of the term of the lease or the estimated useful lives of the assets. Furniture and fixtures are depreciated using the straight-line method over the estimated useful lives of the assets of 5 years. Computer equipment and software are depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 5 years.
Development Stage Company Policy [Policy Text Block]	'
	Internal-Use Software Development Costs
	The Company capitalizes certain costs associated with the purchase and/or development of internal-use software, including its website. Generally, external and internal costs incurred during the application development stage of a project are capitalized. The application development stage of a project generally includes software design and configuration, coding, testing and installation activities. Training and maintenance costs are expensed as incurred. Upgrades and enhancements are capitalized if it is probable that such expenditures will result in additional functionality. Capitalized software costs are amortized using the straight-line method over the estimated useful life of the asst, which approximates 3 years.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	Long-Lived Assets
	Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Company assesses recoverability by determining whether the net book value of the related asset will be recovered through the projected undiscounted future cash flows of the asset. If the Company determines that the carrying value of the asset may not be recoverable, it measures any impairment based on the fair value of the asset as compared to its carrying value. During the six months ended June 30, 2013 and the year ended December 31, 2012, the Company did not record any impairment charges.
Investment, Policy [Policy Text Block]	'
	Investments Held in Trust
	The Company applies the provisions of ASC Topic 320-10, Investment – Debt and Equity, to account for investments held in trust, which comprise only of held-to maturity securities. Held-to-maturity securities are those securities, which the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost on the accompanying balance sheets and adjusted for any amortization or accretion of premiums or discounts.
Deferred Charges, Policy [Policy Text Block]	'
	Deferred Financing Costs
	Costs relating to obtaining the line of credit in April 2013 and the Bridge Notes in September 2012 have been capitalized and amortized over the term of the related debt using the straight line method. Amortization of deferred financing costs charged to interest expense was $686,631 and $254,993 in the six months ended June 30, 2013 and for the year ended December 31, 2013, respectively. The unamortized balance was $548,394 and $552,380 at June 30, 2013 and December 31, 2012, respectively.
Derivatives, Policy [Policy Text Block]	'
	Derivative Financial Instruments
	The Company applies the provisions of ASC Topic 815-40, Contracts in Entity’s Own Equity (“ASC Topic 815-40”), under which convertible instruments and warrants, which contain terms that protect holders from declines in the stock price (reset provisions), may not be exempt from derivative accounting treatment. As a result, such warrants are recorded as a liability and are revalued at fair value at the end of each reporting period. Furthermore, under derivative accounting, the warrants are initially recorded at their fair value. If the fair value of the warrants exceeds the face value of the related debt, the excess is recorded as a change in fair value in the statement of operations on the issuance date.
Debt, Policy [Policy Text Block]	'
	Debt Discounts
	Debt discounts are amortized using the effective interest rate method over the term of the related debt. The result achieved using the straight-line method is not materially different than those which would result using the effective interest method.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Share-Based Payments
	Share-based payments to employees are measured at the fair value of the award on the date of grant based on the estimated number of awards that are ultimately expected to vest. The compensation expense resulting from such awards is recorded over the vesting period of the award in selling, general and administrative expenses on the accompanying consolidated statements of operations.
	Share-based payments to non-employees for services rendered are recorded at either the fair value of the services rendered, or the fair value of the awards, whichever is more readily determinable. The expense resulting from such awards is  marked to market over the vesting period of the award in selling, general and administration expenses on the accompanying consolidated statements of operations.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company typically enters into annual renewable agreements with its customers to provide pharmacy benefit management on a fixed price or self-insured basis. The Company records revenues from all its current contracts with customers gross as the Company acts as principal based on the following factors: 1) the Company has a separate contractual relationship with its customers and with its claims adjudicator to whom the Company pays the costs of the prescription drugs consumed by its customers (the claims), 2) the Company through its claim adjudicator is responsible to validate and manage the claims, and 3) the Company bears the credit risk for the amount due from the customers. Revenues are recorded monthly as earned. The Company also operates a mail order pharmacy that services plan members. All revenues and associated costs from dispensing drugs by the mail order pharmacy to our plan members, excluding the members’ co-pay are eliminated as inter-company revenues. Some of the contracts contain terms whereby the Company makes certain financial guarantees regarding prescription costs. Actual performance is compared to the guaranteed measure throughout the period and accruals are recorded as an offset to revenue if the Company fails to meet a financial guarantee.
Cost of Sales, Policy [Policy Text Block]	'
	Cost of Sales
	Cost of sales includes claim payments for both fixed- price and self-insured programs, administrative fees paid for processing the claims to the claims adjudicator and, the cost of prescription drugs of the mail order pharmacy.
Advertising Costs, Policy [Policy Text Block]	'
	Advertising Expenses
	Advertising expenses are expensed as incurred and included in selling, general and administrative expenses on the accompanying statements of operations. Advertising expenses were approximately $68,000 and $143,000 for the six months ended June 30, 2013 and year ended December 31, 2012, respectively.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance is established when realization of net deferred tax assets is not considered more likely than not.
	Uncertain income tax positions are determined based upon the likelihood of the positions being sustained upon examination by taxing authorities. The benefit of a tax position is recognized in the consolidated financial statements in the period during which management believes it is more likely than not that the position will not be sustained. Income tax positions taken are not offset or aggregated with other positions. Income tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of income tax benefit that is more than 50 percent likely of being realized if challenged by the applicable taxing authority. The portion of the benefits associated with income tax positions taken that exceeds the amount measured is reflected as income taxes payable.
	The Company recognizes interest related to uncertain tax positions in interest expense. The Company recognizes penalties related to uncertain tax positions in income tax expense.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair Value Measurements
	The Company applies recurring fair value measurements to its derivative instruments in accordance with ASC 820, Fair Value Measurements. In determining fair value, the Company uses a market approach and incorporates assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation techniques. These inputs can be readily observable, market corroborated or generally unobservable internally-developed inputs. Based upon the observability of the inputs used in these valuation techniques, the Company’s derivative instruments are classified as follows:
		Level 1:	The fair value of derivative instruments classified as Level 1 is determined by unadjusted quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date.
		Level 2:	The fair value of derivative instruments classified as Level 2 is determined by quoted market prices for similar assets or liabilities in active markets, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data.
		Level 3:	The fair value of derivative instruments classified as Level 3 is determined by internally-developed models and methodologies utilizing significant inputs that are generally less readily observable from objective sources.
	The Company’s valuation methodology for warrants classified as derivative liabilities qualifies as a level 2 fair value measurement since it is determined using internally developed models and analysis.
	At June 30, 2013 the Company had 2,000,000 warrants exercisable into its Class C shares that were issued in connection with Selway’s initial public offering (“Selway IPO Warrants”). These warrants are publicly traded and are classified as liabilities. Additionally, HCCA issued 296,250 warrants in connection with the Bridge Financing with identical terms as the Selway IPO Warrants. The Company has valued all of these warrants as June 30, 2013 based on the closing price of the Selway IPO Warrants. Because the market for the Selway IPO Warrants is not active, the valuation is classified as a Level 2 measurement. These warrants are exercisable at $7.50 a share and expire on November 7, 2016.
	The table below presents the Company’s fair value hierarchy for those derivative instruments measured at fair value on a recurring basis as of June 30, 2013:
			Level 1		Level 2		Level 3		Total
	Warrants		$	-	$	3,559,188	$	-	$	3,559,188
	Total derivative liabilities		$	-	$	3,559,188	$	-	$	3,559,188
	The table below presents the Company’s fair value hierarchy for those derivative instruments measured at fair value on a recurring basis as of December 31, 2012:
			Level 1		Level 2		Level 3		Total
	Warrants		$	-	$	121,350	$	-	$	121,350
	Total derivative liabilities		$	-	$	121,350	$	-	$	121,350
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The fair values of cash and cash equivalents, accounts receivable, rebates receivable and accounts payable approximate their carrying values due to the short-term nature of the instruments. The fair values of long-term debt and revolving loans approximates their carrying value due to their variable interest rates. The fair value of investments held in trust is not materially different than its carrying value because of the short-term nature of the investments.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Risks and Concentrations
	The Company utilizes the services of a single claims adjudicator. If there is an adverse situation in this relationship, the Company’s mail order pharmaceutical fulfillment services would be ineffective until a replacement claims adjudicator was obtained.
	Approximately 12% of the Company’s 2012 revenues were derived from one customer. Revenues from this customer were 10% of our revenues for the six month period ended June 30, 2013. No amounts were due from this customer at June 30, 2013 or December 31, 2012. In addition, one of the reseller’s customers accounted for approximately 14% of the Company’s revenue for the six month period ended June 30, 2013 as well as approximately 14% of the Company’s revenue for the year ended December 31, 2012. Amounts due from this customer represented 32% and 46% of accounts receivable at June 30, 2013 and December 31, 2012, respectively.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	The Company considers all cash in bank, money market funds and certificates of deposit with an original maturity of less than three months to be cash equivalents. The Company maintains its cash and cash equivalents in one financial institution. Cash balances on hand at this financial institution may exceed the insurance coverage provided to the Company by the Federal Deposit Insurance Corporation at various times during the year.
Earnings Per Share, Policy [Policy Text Block]	'
	Earnings (Loss) Per Share
	Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share are determined in the same manner as basic earnings (loss) per share, except that the number of shares is increased to include potentially dilutive securities using the treasury stock method. Because the Company incurred a net loss in all periods presented, all potentially dilutive securities were excluded from the computation of diluted loss per share because the effect of including them is anti-dilutive.
			Six Months Ended		Year Ended
			June 30, 2013		December 31, 2012
	Basic and Diluted:
	Net loss		$	-14,066,292	$	-7,575,965
	Less: Deemed dividend to preferred stockholders			-3,532,858		-
	Net loss attributable to common stockholders		$	-17,599,150	$	-7,575,965
	Weighted average shares			6,851,819		38,939,909
	Basic loss per common share		$	-2.57	$	-0.19
	The following table summarizes the number of shares of common stock attributable to potentially dilutive securities outstanding for each of the periods which are excluded in the calculation of diluted loss per share:
			Six Months Ended		Year Ended
			June 30, 2013		December 31, 2012
	Dilutive Potential Common Shares
	Warrants		$	3,314,023	$	1,585,833
	Restricted stock awards			-		75,292
	Convertible notes payable			-		2,666,667
Reclassification, Policy [Policy Text Block]	'
	Reclassification
	Certain previously reported amounts have been reclassified to conform to the presentation used in the June 30, 2013 financial statements.

Restatement_Tables

Restatement (Tables)	6 Months Ended
	Jun. 30, 2013
Restatement [Abstract]	'
Schedule Subsequent And First Restated Statements [Table Text Block]	'
	The following table represents the effects of the subsequent and first restated statements as of December 31, 2012:
		Subsequent		First
		Restatement		Restated		Original
		December 31, 2012		December 31, 2012		December 31, 2012
	Accounts receivable	$	1,126,846	$	572,637	$	1,220,065
	Rebates receivable	$	1,323,474	$	1,323,474	$	1,638,000
	Other receivables	$	40,867	$	40,867	$	40,867
	Accounts payable	$	4,431,366	$	4,520,223	$	1,514,857
	Accrued expenses	$	568,528	$	453,057	$	453,057
	Note payable	$	4,192,954	$	4,947,613	$	4,947,613
	Redeemable preferred stock	$	2,362,517	$	458,800	$	458,800
	Warrant liability	$	121,350	$	518,587	$	518,587
	Common stock	$	4,175,856	$	3,556,056	$	3,556,056
	APIC	$	150,000	$	-	$	-
	Sales	$	27,305,795	$	28,663,284	$	38,401,140
	Cost of sales	$	26,148,118	$	24,068,906	$	31,650,232
	General and administrative expenses	$	7,603,458	$	7,299,603	$	7,299,603
	Interest expense	$	-1,130,184	$	640,286	$	640,286
	Accumulated deficit	$	-10,639,542	$	-8,937,860	$	-4,970,540
	Loss per share	$	-0.19	$	-0.09	$	-0.02

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2013
Accounting Policies [Abstract]	'
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	'
	The table below presents the Company’s fair value hierarchy for those derivative instruments measured at fair value on a recurring basis as of June 30, 2013:
		Level 1		Level 2		Level 3		Total
	Warrants	$	-	$	3,559,188	$	-	$	3,559,188
	Total derivative liabilities	$	-	$	3,559,188	$	-	$	3,559,188
	The table below presents the Company’s fair value hierarchy for those derivative instruments measured at fair value on a recurring basis as of December 31, 2012:
		Level 1		Level 2		Level 3		Total
	Warrants	$	-	$	121,350	$	-	$	121,350
	Total derivative liabilities	$	-	$	121,350	$	-	$	121,350
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following table summarizes the number of shares of common stock attributable to potentially dilutive securities outstanding for each of the periods which are excluded in the calculation of diluted loss per share:
		Six Months Ended		Year Ended
		June 30, 2013		December 31, 2012
	Basic and Diluted:
	Net loss	$	-14,066,292	$	-7,575,965
	Less: Deemed dividend to preferred stockholders		-3,532,858		-
	Net loss attributable to common stockholders	$	-17,599,150	$	-7,575,965
	Weighted average shares		6,851,819		38,939,909
	Basic income (loss) per common share	$	-2.57	$	-0.19
Diluted Loss Per Shares [Table Text Block]	'
	The following table summarizes the number of shares of common stock attributable to potentially dilutive securities outstanding for each of the periods which are excluded in the calculation of diluted loss per share:
		Six Months Ended		Year Ended
		June 30, 2013		December 31, 2012
	Dilutive Potential Common Shares
	Warrants	$	3,314,023	$	1,585,833
	Restricted stock awards		-		75,292
	Convertible notes payable		-		2,666,667

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment is as follows:
		June 30, 2013		December 31, 2012
	Furniture, fixtures and equipment	$	1,606,404	$	1,374,126
	Leasehold improvements		25,260		10,162
			1,631,664		1,384,288
	Accumulated depreciation and amortization		-394,930		-270,233
	Net property and equipment	$	1,236,734	$	1,114,055

Software_net_Tables

Software, net (Tables)	6 Months Ended
	Jun. 30, 2013
Capitalized Computer Software, Net [Abstract]	'
Schedule of Capitalized Computer Software, Net [Table Text Block]	'
	Software, net is as follows:
		June 30, 2013		December 31, 2012
	Software costs	$	294,109	$	-
	Accumulated amortization		-31,967		-
	Net software costs	$	262,142	$	-

Deferred_Financing_Costs_Table

Deferred Financing Costs (Tables)	6 Months Ended
	Jun. 30, 2013
Deferred Finance Costs [Abstract]	'
Schedule of Fresh-Start Adjustments [Table Text Block]	'
	Deferred financing costs are as follows:
	Balance January 1, 2013	$	-
	Costs incurred for line of credit for the six months ended June 30, 2013		615,754
	Amortization for the six monthes ended June 30, 2013		-67,360
	Balance June 30, 2013	$	548,394

Accrued_Expenses_Tables

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued expenses are as follows:
			June 30, 2013		December 31, 2012
	Accrued severence costs*		$	750,000	$	-
	Accrued rebates			364,196		77,329
	Accrued registration rights penalties**			592,000		-
	Accrued professional fees			290,777		50,000
	Accrued expenses other			431,060		441,199
			$	2,428,033	$	568,528
		*	Payable to a former executive of the Company.
		**	Estimated penalties relating to late registration of shares of common stock in connection with the bridge notes.

LongTerm_Debt_Tables

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2013
Long-term Debt and Capital Lease Obligations, Current [Abstract]	'
Schedule of Share-based Compensation, Nonemployee Director Stock Award Plan, Activity [Table Text Block]	'
		June 30, 2013
	Shareholder notes	$	7,500,000
	Placement notes		500,000
	Management incentive notes		2,500,000
			10,500,000
	Less debt discount		-7,728,486
		$	2,771,514
Schedule of Maturities of Long-term Debt [Table Text Block]	'
	Future maturities of the Incentive Notes based on the Company’s estimates are as follows:
	June 30,
	2014	$	-
	2015		-
	2016		399,000
	2017		1,789,000
	2018		3,622,000
	Thereafter		4,690,000
		$	10,500,000
Schedule of Capital Leased Assets [Table Text Block]	'
	The Company has entered into capital lease agreements for equipment, which expire at various dates through November 2019. The assets capitalized under these leases and associated accumulated depreciation at June 30, 2013 and December 31, 2012 are as follows:
		June 30, 2013		December 31, 2012
	Furniture and equipment	$	1,007,735	$	584,638
	Accumulated depreciation		-250,821		-153,937
		$	756,914	$	430,701
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	'
	Minimum future lease payments under capital lease obligations as of June 30, 2013 are as follows:
	Year Ended June 30,
	2014	$	256,257
	2015		242,040
	2016		209,938
	2017		158,814
	2018		106,617
	Thereafter		50,640
	Total future minimum lease payments		1,024,306
	Less amount representing interest		-176,225
	Present value of net minimum lease payments		848,081
	Less current portion		-189,989
		$	658,092

Income_Taxes_Tables

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	Deferred tax assets are as follows:
		June 30, 2013		December 31, 2012
	Loss carryforwards	$	6,363,018	$	2,064,222
	Intangible assets		81,000		44,000
	Accrued expenses		1,060,000		1,060,000
	Stock based compensation		209,904		-
	Fixed assets		7,409		-14,120
	Less valuation allowance		-7,721,331		-3,154,102
	Total net deferred tax assets	$	-	$	-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	A reconciliation of income taxes at the U.S. federal statutory rate to the income expense is as follows:
		Six Months and Year Ended
		June 30, 2013		December 31, 2012
	U.S. Federal statutory rate	-34	%	-34	%
	State income taxes, net of federal benefit	-5.9		-5.9
	Permanent differences	-0.2		0.2
	Interest expense	7.9		-
	Change in valuation allowance	32.2	%	39.7	%
	Effective tax rate	-	%	-	%

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	Future minimum payments for non-cancelable operating leases are as follows as of June 30, 2013:
	Minimum Rental Payments
	2014	$	207,764
	2015		206,251
	2016		217,740
	2017		146,520
		$	778,275

Selected_Financial_Data_unaudi1

Selected Financial Data (unaudited) (Tables)	6 Months Ended
	Jun. 30, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information [Table Text Block]	'
		Six months ended
		June 30, 2012
	Revenue	$	10,056,735
	Gross profit	$	426,730
	Loss before income taxes	$	-2,490,381
	Net loss	$	-2,495,461
	Basic and diluted net income per share	$	-0.07
	Weighted average number of shares outstanding		37,897,909

Liquidity_and_Financial_Condit1

Liquidity and Financial Condition (Details Textual) (USD $)	6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Liquidity and Financial Condition [Line Items]	'	'	'	'
Working Capital Deficit	$3,640,546	'	$4,564,045	'
Stockholders' Equity Attributable To Parent	-8,281,522	'	-3,951,169	2,824,234
Net Income (Loss) Attributable To Parent	-14,066,292	-2,495,461	-7,575,965	'
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	$4,784,185	'	$7,921,407	'

The_Merger_Details_Textual

The Merger (Details Textual) (USD $)

6 Months Ended

12 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

Jun. 30, 2013

Dec. 31, 2012

Dec. 31, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Subsequent Event [Member]

Subsequent Event [Member]

Incentive Stock [Member]

Series C Common Stock [Member]

Series A Common Stock [Member]

Bridge Financing [Member]

Bridge Financing [Member]

Minimum [Member]

Maximum [Member]

Warrant [Member]

Criteria [Member]

Notes Payable, Other Payables [Member]

Bridge Loan [Member]

Bridge Loan [Member]

Healthcare Corporation Of America [Member]

Healthcare Corporation Of America [Member]

Healthcare Corporation Of America [Member]

Escrow [Member]

Earnout Payment Shares [Member]

Earnout Payment Shares [Member]

Earnout Payment Shares [Member]

Chardan Capital Markets Llc [Member]

Management Incentive Shares [Member]

Management Incentive Shares [Member]

Management Incentive Shares [Member]

Management Incentive Shares [Member]

Series C Common Stock [Member]

Series C Common Stock [Member]

Bridge Financing [Member]

Notes Payable, Other Payables [Member]

Healthcare Corporation Of America [Member]

Healthcare Corporation Of America [Member]

Healthcare Corporation Of America [Member]

Healthcare Corporation Of America [Member]

Healthcare Corporation Of America [Member]

June 30, 2014 [Member]

June 30, 2015 [Member]

Rescission Agreements [Member]

Promissory Note [Member]

Criteria One [Member]

Criteria Two [Member]

Business Acquisition, Equity Interests Issued or Issuable [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Acquisition, Equity Interest Issued or Issuable, Number of Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,200,000

592,500

'

'

2,800,000

1,400,000

1,400,000

546,002

1,500,000

'

'

'

Business Acquisition Cost Of Acquired Entity Purchase Prices

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7,500,000

'

'

'

'

'

'

'

'

Business Acquisition, Notes Repayment Description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The notes will be repaid from 18.5% of the Companys free cash-flow (as defined) in excess of $2,000,000.

'

'

'

'

'

'

'

'

'

'

'

Liabilities Assumed

6,327,559

'

'

'

'

'

'

'

'

'

'

'

'

1,977,570

'

'

'

'

1,977,570

'

'

'

'

'

'

'

'

'

Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Cancelled

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

750,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

350,000

'

Merger Agreement, Shares Vesting Terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Certain members of HCCAs management received an aggregate of 1,500,000 shares of our common stock (the Management Incentive Shares), which shares were placed in escrow and subject to release in three installments through June 30, 2015.

'

'

'

Class Of Warrant Or Rights Issued

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

7.5

'

'

'

'

'

'

'

'

'

'

'

7.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of Warrants

0

371,350

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

'

'

'

6-Nov-16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15

'

'

'

'

'

'

'

'

'

'

'

Criteria For Payment Of Earn Out Payment Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'(i) 1,400,000 shares if the Company achieves consolidated gross revenue of $150,000,000 for the twelve months ended March 31, 2014 or June 30, 2014

'(ii) 1,400,000 shares if the Company achieves consolidated gross revenue of $300,000,000 for the twelve months ended March 31, 2015

'

'

'

'

'

Bridge Financing Units Issued Warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

59.25

'

'

'

'

'

'

'

'

'

'

'

Bridge Financing, Units Issued, Preferred Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

'

'

'

'

'

Bridge Financing, Promissory Note Face Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

296,250

'

'

'

'

'

'

'

'

'

'

Preferred Stock Dividends, Income Statement Impact

3,532,858

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,532,858

'

'

'

'

'

'

'

'

'

'

Class Of Warrant Or Right Exercisable Warrants Or Rights Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7.50

'

'

'

'

'

'

'

'

'

'

'

'

'

Class Of Warrant Or Right Expired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7-Nov-16

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

5.00%

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Promissory Note Convertible Into Common Stock

'

'

'

'

'

10,000

'

'

315,959

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of Debt Discount (Premium)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,018,851

'

'

'

'

'

'

'

'

'

'

'

Interest Expense, Debt

1,732,047

713,196

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

7,728,486

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,445,242

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Additional Interest Expense

1,182,327

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Annual Principal Payment

'

'

'

'

'

'

3,101,038

3,159,624

'

'

'

'

'

'

'

3,025,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Periodic Payment, Principal

'

'

'

'

'

'

'

3,025,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Expense, Other Long-term Debt

592,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Rate

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Converted

878,481

'

'

'

'

'

'

'

'

'

'

'

'

'

'

281,554

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

$1.50

'

'

$3.53

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Amount Converted

'

'

'

'

'

11,948,361

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion Of Stock To Underwriters

237,007

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Transaction Cost Total

577,069

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate Shares Of Common Stock For Placement Warrant

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

1,000,000

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage For Holders Issued And Outstanding Shares

75.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage For Members Of Management

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description For Warrants Exercisable

'common stock exceeds $12.00 per share for 20 trading days in any 30-trading-day period.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class Of Warrant Or Right Initial Exercise Price Of Warrants

$7.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class Of Warrant Or Right Exercise Price Of Warrants Adjustment

'

'

'

'

'

'

'

'

'

$1.50

$7.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage For Consideration Received Owed To Adviser

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Other

'

'

'

'

335,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Common Stock And Incentive Stock

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Incentive Note Issued

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Incentive Note Issued

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description For Business Acquisition Transaction Factors

'The majority of shares of the Company post-closing were still owned by HCCA shareholders, who represented 60% of the Companys shares outstanding immediately after closing, if all shares subject to conversion in our post-closing tender offer actually convert to Series C (non-redeemable) common shares, and 65% of the Companys shares outstanding if all shares subject to conversion do not convert to Series C shares and opt to receive their pro rata cash in trust at the time of the post-closing tender offer. Estimates of HCCAs ownership do not include shares underlying warrants held by public investors and the Companys sponsors restricted incentive shares held by management. However, HCCA shareholders would still have 51% of the Companys shares post-closing when including shares underlying warrants and restricted shares and assuming all redeemable shares convert to Series C shares, and 54% of the Companys shares post-closing if all shares subject to conversion do not convert to Series C shares and opt to receive their pro rata cash in trust at the time of the post-closing tender offer.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration Risk, Percentage

10.00%

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

Consolidated Gross Revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$150,000,000

$300,000,000

'

'

'

'

'

Conversion Of Preferred Stock Shares Converted Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.70%

'

'

'

'

'

'

'

'

'

'

'

Restatement_Details

Restatement (Details) (USD $)	1 Months Ended	6 Months Ended		12 Months Ended
	Sep. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
Schedule Subsequent And First Restated Statements [Line Items]	'	'	'	'
Accounts receivable	'	$1,251,579	'	$1,126,846
Rebates receivable	'	1,574,659	'	1,323,474
Other receivables	'	857	'	40,867
Accounts payable	'	5,214,355	'	4,431,366
Accrued expenses	'	2,428,033	'	568,528
Note payable	'	0	'	4,192,954
Redeemable preferred stock	'	0	'	2,362,517
Warrant liability	'	3,559,188	'	121,350
Common stock	'	895	'	4,175,856
APIC	'	16,423,417	'	150,000
Sales	'	24,328,860	'	27,305,795
Cost of sales	'	23,309,725	'	26,148,118
General and administrative expenses	641,142	'	'	7,603,458
Interest expense	'	'	'	-1,130,184
Accumulated deficit	'	-24,705,834	'	-10,639,542
Loss per share	'	($2.57)	($0.07)	($0.19)
First Restated [Member]	'	'	'	'
Schedule Subsequent And First Restated Statements [Line Items]	'	'	'	'
Accounts receivable	'	'	'	572,637
Rebates receivable	'	'	'	1,323,474
Other receivables	'	'	'	40,867
Accounts payable	'	'	'	4,520,223
Accrued expenses	'	'	'	453,057
Note payable	'	'	'	4,947,613
Redeemable preferred stock	'	'	'	458,800
Warrant liability	'	'	'	518,587
Common stock	'	'	'	3,556,056
APIC	'	'	'	0
Sales	'	'	'	28,663,284
Cost of sales	'	'	'	24,068,906
General and administrative expenses	'	'	'	7,299,603
Interest expense	'	'	'	640,286
Accumulated deficit	'	'	'	-8,937,860
Loss per share	'	'	'	($0.09)
Original [Member]	'	'	'	'
Schedule Subsequent And First Restated Statements [Line Items]	'	'	'	'
Accounts receivable	'	'	'	1,220,065
Rebates receivable	'	'	'	1,638,000
Other receivables	'	'	'	40,867
Accounts payable	'	'	'	1,514,857
Accrued expenses	'	'	'	453,057
Note payable	'	'	'	4,947,613
Redeemable preferred stock	'	'	'	458,800
Warrant liability	'	'	'	518,587
Common stock	'	'	'	3,556,056
APIC	'	'	'	0
Sales	'	'	'	38,401,140
Cost of sales	'	'	'	31,650,232
General and administrative expenses	'	'	'	7,299,603
Interest expense	'	'	'	640,286
Accumulated deficit	'	'	'	($4,970,540)
Loss per share	'	'	'	($0.02)

Significant_Accounting_Policie3

Significant Accounting Policies (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Significant Accounting Policies [Line Items]	'	'
Total derivative liabilities	$3,559,188	$121,350
Warrant Liability [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Warrants	3,559,188	121,350
Fair Value, Inputs, Level 1 [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Total derivative liabilities	0	0
Fair Value, Inputs, Level 1 [Member] | Warrant Liability [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Warrants	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Total derivative liabilities	3,559,188	121,350
Fair Value, Inputs, Level 2 [Member] | Warrant Liability [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Warrants	3,559,188	121,350
Fair Value, Inputs, Level 3 [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Total derivative liabilities	0	'
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]	'	'
Significant Accounting Policies [Line Items]	'	'
Warrants	$0	'

Significant_Accounting_Policie4

Significant Accounting Policies (Details 1) (USD $)	6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
Basic and Diluted:	'	'	'
Net loss	($14,066,292)	'	($7,575,965)
Less: Deemed dividend to preferred stockholders	-3,532,858	'	0
Net loss attributable to common stockholders	($17,599,150)	'	($7,575,965)
Weighted average shares (in shares)	6,851,819	37,897,909	38,939,909
Basic income (loss) per common share (in dollars per share)	($2.57)	($0.07)	($0.19)

Significant_Accounting_Policie5

Significant Accounting Policies (Details 2) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Dilutive Potential Common Shares	'	'
Warrants	$3,314,023	$1,585,833
Restricted stock awards	0	75,292
Convertible notes payable	$0	$2,666,667

Significant_Accounting_Policie6

Significant Accounting Policies (Details Textual) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Significant Accounting Policies [Line Items]	'	'	'
Allowance for Doubtful Accounts Receivable	$0	'	$0
Impairment of Long-Lived Assets Held-for-use	0	0	'
Amortization of Financing Costs	-67,360	254,993	'
Postconfirmation, Deferred Financing Costs	548,394	552,380	'
Advertising Expense	68,000	'	143,000
Warrants Issued During Period	2,000,000	'	'
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants	$296,250	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	7.5	'	'
Warrants Expiration Date	7-Nov-16	'	'
Concentration Risk, Percentage	10.00%	'	12.00%
Percentage Portion In Accounts Receivable	32.00%	'	46.00%
Customer [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Concentration Risk, Percentage	14.00%	'	14.00%
Furniture and Fixtures [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'5 years	'	'
Computer Equipment And Software [Member] | Minimum [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'3 years	'	'
Computer Equipment And Software [Member] | Maximum [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'5 years	'	'
Software and Software Development Costs [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Property, Plant and Equipment, Useful Life	'3 years	'	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Furniture, fixtures and equipment	$1,606,404	$1,374,126
Leasehold improvements	25,260	10,162
Property, Plant and Equipment, Gross	1,631,664	1,384,288
Accumulated depreciation and amortization	-394,930	-270,233
Net property and equipment	$1,236,734	$1,114,055

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012
Property, Plant and Equipment [Line Items]	'	'
Depreciation, Depletion and Amortization, Nonproduction, Total	$124,700	$206,000

Software_net_Details

Software, net (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Capitalized Computer Software, Net [Line Items]	'	'
Software costs	$294,109	$0
Accumulated amortization	-31,967	0
Net software costs	$262,142	$0

Software_net_Details_Textual

Software, net (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2013
Capitalized Computer Software, Net [Line Items]	'
Amortization, Total	$32,000

Investments_Held_in_Trust_Deta

Investments Held in Trust (Details Textual) (USD $)	1 Months Ended
	Nov. 30, 2011	Apr. 10, 2013
Investments Held in Trust [Line Items]	'	'
Investments and Cash Held In Trust	$20,600,000	'
Temporary Equity, Shares Outstanding	'	1,160,035
Escrow Deposit Disbursements Related To Shares Redeemption	'	11,948,000
Trust Account Balance	'	$8,652,000
Temporary Equity Shares Outstanding Redeemable Shares	'	839,965

Deferred_Financing_Costs_Detai

Deferred Financing Costs (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2013
Deferred Financing Costs [Line Items]	'	'
Balance January 1, 2013	$0	$0
Costs incurred for line of credit for the six months ended June 30, 2013	615,754	'
Amortization for the six monthes ended June 30, 2013	-67,360	254,993
Balance June 30, 2013	$548,394	'

Accured_Expenses_Details

Accured Expenses (Details) (USD $)	Jun. 30, 2013		Dec. 31, 2012
Accrued Expenses [Line Items]	'		'
Accrued severence costs	$750,000	[1]	$0	[1]
Accrued rebates	364,196		77,329
Accrued registration rights Penalties	592,000	[2]	0	[2]
Accrued professional fees	290,777		50,000
Accrued expenses other	431,060		441,199
Accrued Liabilities, Total	$2,428,033		$568,528
[1]	Payable to a former executive of the Company.
[2]	Estimated penalties relating to late registration of shares of common stock in connection with the bridge notes.

Line_of_Credit_Details_Texual

Line of Credit (Details Texual) (USD $)	0 Months Ended
	Apr. 11, 2013	Jun. 30, 2013
Line of Credit Facility [Line Items]	'	'
Line of Credit Facility, Maximum Borrowing Capacity	$5,000,000	'
Line of Credit Facility, Expiration Period	'3 years	'
Line of Credit Facility, Amount Outstanding	'	$534,343

Bridge_Notes_Details_Textual

Bridge Notes (Details Textual) (USD $)	1 Months Ended	6 Months Ended
	Sep. 12, 2012	Jun. 30, 2013	Dec. 31, 2012
Disclosure Of Bridge Notes [Line Items]	'	'	'
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants	'	$296,250	'
Stock Issued During Period, Value, Conversion of Convertible Securities	'	3,159,624	'
Preferred Stock, Value, Issued	'	0	2,362,517
Debt Instrument, Unamortized Discount	'	7,728,486	'
Loan Processing Fee	673,229	'	'
Series C Common Stock [Member]	'	'	'
Disclosure Of Bridge Notes [Line Items]	'	'	'
Debt Instrument, Annual Principal Payment	3,025,000	'	'
Bridge Financing [Member]	'	'	'
Disclosure Of Bridge Notes [Line Items]	'	'	'
Fair Value Of Warrant Liability	82,726	'	'
Preferred Stock, Value, Issued	2,362,517	'	'
Notes Payable, Fair Value Disclosure	3,479,757	'	'
Debt Instrument, Unamortized Discount	2,445,242	'	'
Bridge Financing [Member] | Series C Common Stock [Member]	'	'	'
Disclosure Of Bridge Notes [Line Items]	'	'	'
Stock Issued During Period, Value, Conversion of Convertible Securities	3,159,592	'	'
Stock Issued During Period, Shares, Conversion of Convertible Securities	315,959	'	'
Healthcare Corporation Of America [Member]	'	'	'
Disclosure Of Bridge Notes [Line Items]	'	'	'
Bridge Financing, Units Issued	59.25	'	'
Healthcare Corporation Of America [Member] | Series C Common Stock [Member]	'	'	'
Disclosure Of Bridge Notes [Line Items]	'	'	'
Stock Issued During Period, Shares, Conversion Of Redeemable Preferred Stock And Warrants	592,500	'	'
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants	296,250	'	'
Healthcare Corporation Of America [Member] | Bridge Financing [Member]	'	'	'
Disclosure Of Bridge Notes [Line Items]	'	'	'
Bridge Financing, Units Issued, Preferred Shares	10,000	'	'
Bridge Financing, Promissory Note Face Value	$100,000	'	'
Bridge Financing Units Issued Warrants	5,000	'	'

LongTerm_Debt_Details

Long-Term Debt (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'
Long-term Debt, Total	$10,500,000	'
Less debt discount	-7,728,486	'
Other Long-term Debt, Noncurrent	2,771,514	0
Shareholder Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Total	7,500,000	'
Placement Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Total	500,000	'
Management Incentive Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Total	$2,500,000	'

LongTerm_Debt_Details_1

Long-Term Debt (Details 1) (USD $)	Jun. 30, 2013
Schedule of Capitalization, Long-term Debt [Line Items]	'
2014	$0
2015	0
2016	399,000
2017	1,789,000
2018	3,622,000
Thereafter	4,690,000
Long-term debt	$10,500,000

LongTerm_Debt_Details_2

Long-Term Debt (Details 2) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Capital Leased Assets [Line Items]	'	'
Furniture and equipment	$1,007,735	$584,638
Accumulated depreciation	-250,821	-153,937
Capital Leased Assets, Gross	$756,914	$430,701

LongTerm_Debt_Details_3

Long-Term Debt (Details 3) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Capital Leased Assets [Line Items]	'	'
2014	$256,257	'
2015	242,040	'
2016	209,938	'
2017	158,814	'
2018	106,617	'
Thereafter	50,640	'
Total future minimum lease payments	1,024,306	'
Less amount representing interest	-176,225	'
Present value of net minimum lease payments	848,081	'
Less current portion	-189,989	-137,703
Capital Lease Obligations	$658,092	'

LongTerm_Debt_Details_Textual

Long-Term Debt (Details Textual) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'
Stock Issued During Period, Value, New Issues	$0	$650,562
Debt Instrument, Interest Rate, Effective Percentage	25.00%	'
Debt Instrument, Convertible, If-converted Value in Excess of Principal	2,000,000	'
Lease Expiration Date	30-Nov-19	'
Long-term Debt	10,500,000	'
Long-term Debt, Gross	500,000	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Management Incentive Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Management Fees, Incentive Revenue	222,477	'
Payment for Management Fee	395,514	'
Long-term Debt	2,500,000	'
Series C Common Stock [Member]	'	'
Debt Instrument [Line Items]	'	'
Stock Issued During Period, Shares, New Issues	5,200,000	'
Stock Issued During Period, Value, New Issues	7,500,000	'
Senior Debt Obligations [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Face Amount	$10,500,000	'

Redeemable_Securities_Details_

Redeemable Securities (Details Textual) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Redeemable Securities [Line Items]	'	'
Temporary Equity, Redemption Price Per Share	$10.30	'
Common Stock, Shares, Outstanding	8,953,494	40,000,009
Series B Common Stocks [Member]	'	'
Redeemable Securities [Line Items]	'	'
Common Stock, Shares, Outstanding	839,965	'

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2013	Feb. 28, 2013	Dec. 31, 2012
Class of Stock [Line Items]	'	'	'
Common Stock, Shares Authorized	30,000,000	'	50,000,000
Common Stock, Par Or Stated Value Per Share	$0.00	'	$0
Common Stock, Shares, Outstanding	8,953,494	'	40,000,009
Common Stock, Shares, Issued	8,953,494	'	40,000,009
Stock Repurchase Program, Number of Shares Authorized to be Repurchased	'	'	500,000
Common Stock Redemption Amount	'	$100,000	'
Equity Issued in Business Combination, Fair Value Disclosure	'	480,000	'
Stock Issued During Period, Shares, Restricted Stock Award, Gross	750,000	'	'
Share Price	$7.30	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	400,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	2,920,000	'	'
Healthcare Corporation Of America [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Common Stock, Shares Authorized	50,000,000	'	'
Common Stock, Par Or Stated Value Per Share	$0	'	'
Conversion of Stock, Description	'Upon the merger, every 7.6923 HCCA shares of common stock were exchanged into 1 share of the Company's common stock.	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$283,889	'	'
Maximum [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Common Stock, Par Or Stated Value Per Share	'	'	$0.31
Minimum [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Common Stock, Par Or Stated Value Per Share	'	'	$0.01
Series B Common Stock [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Common Stock, Shares, Outstanding	839,965	'	'
Series C Common Stock [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Common Stock, Shares, Outstanding	8,953,494	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	Jun. 30, 2013	Dec. 31, 2012
Income Taxes [Line Items]	'	'
Loss carryforwards	$6,363,018	$2,064,222
Intangible assets	81,000	44,000
Accrued expenses	1,060,000	1,060,000
Stock based compensation	209,904	0
Fixed assets	7,409	-14,120
Less valuation allowance	-7,721,331	-3,154,102
Total net deferred tax assets	$0	$0

Income_Taxes_Details_1

Income Taxes (Details 1)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Income Taxes [Line Items]	'	'
U.S Federal statutory rate	-34.00%	-34.00%
State income taxes, net of federal benefit	-5.90%	-5.90%
Permanent differences	-0.20%	0.20%
Interest expense	7.90%	0.00%
Change in valuation allowance	32.20%	39.70%
Effective tax rate	0.00%	0.00%

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2012
Income Taxes [Line Items]	'	'
Operating Loss Carryforwards, Federal and State	$15,900,000	'
Operating Loss Carryforward Expiration Date	'2035	'
Valuation Allowance, Deferred Tax Asset, Change in Amount	$4,567,229	$2,575,828

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Jun. 30, 2013
Loss Contingencies [Line Items]	'
2014	$207,764
2015	206,251
2016	217,740
2017	146,520
Total	$778,275

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual) (USD $)	0 Months Ended	6 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended	0 Months Ended	6 Months Ended
	Aug. 14, 2012	Jun. 30, 2013	Dec. 31, 2012	Aug. 31, 2013	Dec. 31, 2012	Aug. 31, 2013	Aug. 14, 2012	Jun. 30, 2013
				Subsequent Event [Member]	Litigation [Member]	Litigation [Member]	Litigation [Member]	Employment Agreements [Member]
						Subsequent Event [Member]	Common Stock [Member]
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'
Salaries, Wages and Officers Compensation, Total	'	'	'	'	'	'	'	$2,400,000
Terminated Agreement Annual Compensation	'	'	'	'	'	'	'	1,000,000
Severance Costs	'	'	'	'	'	'	'	120,000
Employee Service Share-Based Compensation Issued Stock Option	'	650,000	'	'	'	'	'	'
Employee Service Share-Based Compensation Additional Stock Option	'	841,000	'	'	'	'	'	'
Loss Contingency, Damages Paid, Value	'	'	'	'	5,000,000	'	'	'
Litigation Settlement, Amount	'	'	'	'	'	2,700,000	'	'
Loss Contingency, Settlement Agreement, Terms	'	'	'	'15 months	'	'	'	'
Stock Issued During Period, Shares, Other	'	'	'	'	'	'	500,000	'
Stock Issued During Period, Value, Other	'	2,920,000	'	'	'	'	100,000	'
Legal Fees	50,000	'	'	'	'	'	'	'
Settlement Of Common Stock But Not Received	'	'	'	'	500,000	'	'	'
Temporary Equity, Redemption Value	'	8,651,639	0	'	100,000	'	'	'
Payments for Rent	'	$96,468	$186,733	'	'	'	'	'

Selected_Financial_Data_unaudi2

Selected Financial Data (unaudited) (Details) (USD $)	6 Months Ended		12 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Dec. 31, 2012
Schedule of Quarterly Financial Information [Line Items]	'	'	'
Revenue	'	$10,056,735	'
Gross profit	1,019,135	426,730	1,157,677
Loss before income taxes	'	-2,490,381	'
Net loss	($14,066,292)	($2,495,461)	($7,575,965)
Basic and diluted net income per share (in dollars per share)	($2.57)	($0.07)	($0.19)
Weighted average number of shares outstanding (in shares)	6,851,819	37,897,909	38,939,909

Related_Party_Details_Textual

Related Party (Details Textual) (USD $)	1 Months Ended	12 Months Ended
	Sep. 30, 2012	Dec. 31, 2012	Jun. 30, 2013
Related Party Transaction [Line Items]	'	'	'
Annual fees for Services	'	'	$360,000
Consulting Agreement Contract Expires	'	'	2-Jan-17
Stock Issued During Period, Shares, Issued for Services	2,068,200	'	'
General and Administrative Expense, Total	$641,142	$7,603,458	'

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (USD $)	6 Months Ended	0 Months Ended	12 Months Ended	0 Months Ended	12 Months Ended
	Jun. 30, 2013	Jul. 15, 2013	Dec. 31, 2013	Aug. 15, 2013	Dec. 31, 2013
	Warrant [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]	Subsequent Event [Member]
				Series B Common stock [Member]	Promissory Note [Member]
Subsequent Event [Line Items]	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	555,000	'	'	'	'
Partners Loan Agreement	'	$5,000,000	'	'	'
Purchase of Common Stock Shares Through Tender Offer	'	'	'	839,965	'
Purchase of Common Stock Value Through Tender Offer	'	'	'	8,650,000	'
Junior Secured Convertible Notes Issued	'	'	2,112,500	'	'
Debt Instrument, Convertible, Conversion Price	'	'	$1.50	'	'
Aggregate Amount Of Notes	'	'	6,000,000	'	'
Percentage Fee On Notes Principal Amount	'	'	'	'	9.00%
Additional Loans	'	'	'	'	500,000
Agent Fee Description	'	'	'	'	'In connection with the Private Placement the Company agreed to pay the Agent a fee representing 9% of the principal amount of the Notes plus the $500,000 additional loan from the Lender, less $250,000, or $2,362,500.
Additional Notes Amount	'	'	'	'	212,625
Loan Principal Amount	'	'	'	'	$2,325,125
Common Stock Exercise Price	'	'	$3	'	'
Number Of Securities Called By Warrants To Be Issued Upon Conversion Of Warrants	'	'	1,550,083	'	'
Number Of Agent Securities Called By Warrants To Be Issued Upon Conversion Of Warrants	'	'	141,750	'	'